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Acronyms and glossary 
ECDC European Centre for Disease Prevention and Control 
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EMCDDA European Monitoring Centre for Drugs and Drug Addiction 
European neighbourhood EU Member States and their geographical land neighbours, EU candidate and 
potential candidate countries, EFTA and EEA countries 
EU European Union 
HAV Hepatitis A virus 
HBV Hepatitis B virus 
HCV Hepatitis C virus 
HIV Human immunodeficiency virus 
Health promotion Health promotion is the process of enabling people to increase control over, and to 
improve, their health. Health promotion includes not only information giving and 
support, but also risk-reduction counselling. 
IGRA Interferon-gamma release assays, a blood test for tuberculosis 
Low-threshold services Low-threshold services are social and health services for people who use drugs; 
they typically offer a place to be, health education and counselling, needle and 
syringe programmes, referral to drug treatment, and sometimes overnight shelter. 
The low-threshold approach aims to reach more users with problematic use 
patterns earlier and to remain in contact with them in order to prevent health 
damage while not requesting abstinence.  
NSP Needle and syringe programmes 
OST Opioid substitution treatment 
Problem drug use Injecting drug use or long-duration/regular use of opioids, cocaine and/or 
amphetamines 
Secondary needle exchange The distribution of sterile injecting equipment to one service user, who then 
redistributes it to others in his or her social network. This is referred to as ‘peer 
distribution’ in some settings. 
STI Sexually transmitted infection 
TB Tuberculosis 
TST Tuberculin skin testing 
UNAIDS Joint United Nations Programme on HIV/AIDS 
WHO World Health Organization 
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Executive summary 
Since the emergence of the HIV epidemic among people who inject drugs in the mid-1980s, many European 
countries have achieved substantial progress in implementing evidence-based measures to prevent and control 
infectious diseases among this group. In the 1990s, EU countries started to develop common prevention policies 
both in the fields of HIV/AIDS and drugs and drug addiction, which included the establishment of EU agencies to 
monitor the drug situation (the EMCDDA in 1993) and to prevent and control infections (ECDC in 2005). In the past 
two decades, prevention and treatment interventions have been expanded and brought to scale. According to 
reports for the year 2009, more than half of the estimated population of problem opioid users received substitution 
treatment, and many countries have established needle and syringe programmes with increasing coverage among 
people who inject drugs. Data from countries with well-established surveillance systems suggest that the number 
of new HIV infections among people who inject drugs has decreased considerably in most, but not all, EU countries 
during the last decade.  
In the European neighbourhood, injecting drug use remains a major factor of vulnerability for acquiring blood-
borne and other infectious diseases, including HIV, hepatitis B and C, tuberculosis, bacterial skin and soft tissue 
infections, and systemic infections. Estimates of the number of people who inject drugs suggest that there are 
significant populations at-risk for these infections in all European countries. Unaddressed, these infections result in 
a large burden on European health systems, significant individual suffering, as well as high treatment costs.  
It has been shown that a pragmatic public health prevention approach can have a strong effect on reducing the 
spread of blood-borne and other infections among people who inject drugs. Prevention is feasible and effective, if 
properly implemented.  
Seven recommended key interventions  
This evidence-based joint guidance by ECDC and the EMCDDA identifies good practice for prevention and control of 
infectious diseases among people who inject drugs.  
Based on the most robust evidence available, expert opinion, and best practice within the EU/EEA, the following 
key intervention components should be applied and, if possible, combined to achieve the maximum prevention 
effect through synergy: 
 
 
Key intervention components 
Injection equipment: Provision of, and legal access to, clean drug injection equipment, including sufficient 
supply of sterile needles and syringes free of charge, as part of a combined multi-component approach, 
implemented through harm-reduction, counselling and treatment programmes. 
Vaccination: Hepatitis A and B, tetanus, influenza vaccines, and, in particular for HIV-positive individuals, 
pneumococcal vaccine. 
Drug dependence treatment: Opioid substitution treatment and other effective forms of drug dependence 
treatment.  
Testing: Voluntary and confidential testing with informed consent for HIV, HCV (HBV for unvaccinated) and 
other infections including TB should be routinely offered and linked to referral to treatment. 
Infectious disease treatment: Antiviral treatment based on clinical indications for those who are HIV, HBV 
or HCV infected. Anti-tuberculosis treatment for active TB cases. TB prophylactic therapy should be considered 
for latent TB cases. Treatment for other infectious diseases should be offered as clinically indicated.  
Health promotion: Health promotion focused on safer injecting behaviour; sexual health, including condom 
use; and disease prevention, testing and treatment. 
Targeted delivery of services: Services should be combined and organised and delivered according to user 
needs and local conditions; this includes the provision of services through outreach and fixed site settings 
offering drug treatment, harm reduction, counselling and testing, and referrals to general primary health and 
specialist medical services.  
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Achieve synergy: combine key interventions 
Recent studies and experience from successful prevention programmes document the added value of offering a 
range of effective intervention measures in the same venues, and of providing a combination of interventions 
according to clients’ needs, to achieve the maximum effect in preventing infections.  
Target audience 
This guidance aims to support policy makers in Europe to plan adequate, evidence-based, pragmatic, and rationally 
designed public health responses for the prevention and control of infections among people who inject drugs. It 
aims at public health programme planners and decision makers working in the fields of infectious diseases, general 
public health, addiction and mental healthcare, social services, and drug control at national and regional levels.  
The guidance is coherent with and supports existing EU-wide policies in the field of drug control and infectious 
diseases and aims to give a comprehensive overview of the best current knowledge in the field, expanding 
previous work to include combinations of key interventions. It also relies on a foundation of core values derived 
from public health and human rights principles, which should guide prevention and service provision. 
Evidence-based public health guidance 
Research results relevant to the guidance have been reviewed and assessed using evidence-based medicine (EBM) 
principles adapted within a public health framework. To produce the guidance, high-level scientific evidence has 
been comprehensively reviewed, and the results were combined with expert knowledge and advice on benefits and 
harms. Best practices as well as user preferences have contributed to the development of key interventions 
suggested in this document.  
National coordination  
A prerequisite to the effective delivery of the key interventions is national and local cooperation, and coordination 
between sectors. National consensus building and mutually respected objectives are essential when it comes to the 
successful implementation of interventions. Objectives should be agreed on by actors across all sectors, particularly 
those that engage with people who inject drugs. 
Tailor measures to the national situation 
In order to ensure that interventions best serve the population of people who inject drugs, as well as prevent and 
control infectious diseases, there must be sufficient surveillance of problem drug use and infections on national and 
sub-national levels. Measures taken should be continuously monitored and evaluated in terms of response, impact, 
relevance and scale of coverage. Investment in adequate surveillance systems of both drug use and infectious 
disease is necessary and cost-effective.  
Evidence suggests that higher levels of coverage of needle and syringe programmes and opioid substitution 
treatment per drug injector are more effective than lower levels of coverage. The goal should be to ensure that the 
services offered meet local needs and demand. Unmet demand for needle and syringe exchange services or 
waiting times for drug treatment indicate inefficiency in prevention.  
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Introduction 
Infections among people who inject drugs 
Since the emergence of the HIV epidemic among people who inject drugs in the mid-1980s, many European 
countries have achieved substantial progress in implementing evidence-based measures to prevent and control 
infectious diseases among this group. In the 1990s, EU countries started developing common prevention policies in 
the fields of HIV/AIDS and drugs and drug addiction, which included the establishment of EU monitoring agencies 
on drugs (in 1993) and infections (in 2005) (3). During subsequent decades, interventions were brought to scale: 
for example, around 700 000 opioid substitution treatments were reported in 2009, more than half of the 
estimated population of problem opioid users (4). The proportion of people who inject drugs among new HIV 
infections and the number of infections in this group decreased considerably in many EU countries. However, in the 
European neighbourhood, injecting drug use remains a major factor of vulnerability for acquiring blood-borne and 
other infectious diseases. Estimates of the number of people who inject drugs suggest that there are significant 
populations at-risk in all European countries (5). Patterns of injection use vary across the region, with opioid 
injection prevalent in all countries and a significant proportion of stimulant (mainly amphetamine) injection in the 
northern and eastern parts of Europe. Poly-drug use further complicates the pattern (5). 
 
 
Common blood-borne infections in this group include human immunodeficiency virus (HIV), hepatitis C virus (HCV), 
and hepatitis B virus (HBV). The main mechanism of transmission for these infections is the sharing of injection 
equipment among users, such as syringes, needles, drug mixing vessels and other drug preparation paraphernalia. 
In addition to spread through shared injection equipment, there is sexual transmission of HIV and HBV, both within 
the population of people who inject drugs and from current or former injectors to their sexual partners or clients. 
While all of the above viral infections are easily transmitted through sharing of used injection equipment, 
transmission risks vary. Compared to HIV infection, hepatitis C infection is characterised by relatively high 
concentrations of virus in the blood, not only during the primary infection phase, but also in those who become 
chronically infected. This is thought to lead to high transmission rates upon exposure to HCV when infected and 
non-infected individuals share needles, syringes or other drug preparation equipment. Hepatitis C prevalence 
normally exceeds HIV prevalence in user communities, and hepatitis C epidemics often precede HIV epidemics 
among people who inject drugs. The higher transmission risk may also explain why HCV is more difficult to limit 
through the application of single interventions, and why higher intervention coverage may be needed to reduce 
HCV rates at population level. 
Infections for which people who inject drugs may be at 
increased risk: 
• HIV infection; 
• hepatitis A; 
• hepatitis B (HBV); 
• hepatitis C (HCV); 
• hepatitis D; 
• tuberculosis (TB) 
• skin and soft tissue infections caused by Staphylococcus aureus (including methicillin-resistant 
Staphylococcus aureus, MRSA) and streptococcal infections (e.g. endocarditis, necrotising fasciitis); 
• severe systemic sepsis (e.g. infections with Clostridium novyi, Bacillus anthracis); 
• STIs other than HIV infection or hepatitis (e.g. chlamydia infection, syphilis and gonorrhoea); 
• respiratory infections such as pneumonia, diphtheria and influenza; 
• wound botulism; 
• tetanus; 
• human T-cell lymphotropic virus (HTLV) infections. 
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While the most recently available European surveillance data suggests that the incidence of HIV infection has 
dropped considerably over the past decade and is further decreasing among people who inject drugs, there are 
clear differences between regions of Europe (6). Many EU Member States experienced large outbreaks of HIV 
infection among people who inject drugs in the 1980s and 1990s, while most countries in the eastern part of the 
European region, including some EU Member States, experienced major outbreaks in the early 2000s. This has led 
to the establishment of high HIV prevalence among active and former drug injectors in several countries within the 
EU. Some east European countries which border the EU have been particularly heavily affected by the rapid spread 
of HIV infections among people who inject drugs. Some EU countries, as well as some neighbouring countries, 
report a high prevalence of co-infection with HIV and tuberculosis among people who inject drugs.  
Figure 1: HIV prevalence among people who inject drugs;  
Europe, 2008–2009 
 
Source: The EMCDDA and Reitox National Focal Points (EMCDDA countries: EU, Croatia, Turkey and Norway); Mathers et al., 
Lancet 2008 (other countries). Colour indicates midpoint of national data, or if not available, of local data. For EMCDDA countries 
data are mostly from 2008–2009. When 2008–2009 data were unavailable, older data were used. The EMCDDA data are sub-
national for Croatia, Netherlands, Turkey, Sweden, United Kingdom, Belgium, Bulgaria, Lithuania, France, Estonia, Ireland; for 
non-EMCDDA countries this information is not available. 
Hepatitis B and C virus infections are common in active and former injectors, and a history of injecting drug use is 
the most frequent risk factor in Europe, particularly for hepatitis C infection. The timing of the introduction of 
hepatitis C infection in this population is less well understood, but the virus is likely to have preceded HIV by a few 
decades. European surveillance data on incidence of new infections are poorly standardised, making it difficult to 
determine trends across the region (7). However, targeted prevalence studies have found high prevalence and 
evidence for frequent outbreaks among users in almost all geographic areas studied (5,8-9). More importantly, 
there is a strong association between the duration of injection drug use and hepatitis C infection (10). Co-infection 
with more than one type of hepatitis, or co-infection with HIV and hepatitis C present growing clinical and 
prevention challenges in many parts of Europe (1).  
10 < 50%
≥ 50%
Not 
included, 
not 
reporting, 
or not 
known
5 < 10%
0 < 5 %
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Figure 2: Prevalence of hepatitis C virus antibodies among people who inject drugs;  
Europe, 2008–2009 
 
Source: The EMCDDA and Reitox National Focal Points (EMCDDA countries: EU, Croatia, Turkey and Norway); Nelson et al., 
Lancet 2011; IHRA, EHRN and WHO Regional Office for Europe (other countries). Colour indicates midpoint of national data, or if 
not available, local data. Data for EMCDDA countries are mostly from 2008–2009. When 2008–2009 data were unavailable, older 
data were used. The EMCDDA data are sub-national for Turkey, UK, France, Slovakia, Netherlands, Belgium, Poland, Bulgaria, 
Spain, Sweden, Ireland, Latvia, Germany, Lithuania, Romania, Estonia. For non-EMCDDA countries, this information is not 
available. 
In addition to HIV and hepatitis B and C, infections caused by human T-lymphotropic virus type II (HTLV-II) have 
been shown to have spread among people who inject drugs as early as the 1970s (11). There have been reports of 
outbreaks of hepatitis A within the EU in groups of people who inject drugs, although isolating the injection risk 
from other risk factors such as poor hygiene is challenging (12-15).  
People who inject drugs, especially those who are socially marginalised, are not only vulnerable to infections from 
blood-borne viruses, but also to other infections. A list of some of these infections is provided in the text box on 
page 3 (16), and additional information on the epidemiology of these diseases is presented in Annex A. These 
include localised bacterial wound and injection site infections, systemic infections, sexually transmitted infections 
and respiratory infections, such as tuberculosis. Cases of tetanus are reported among people who inject drugs. In 
some settings, persons with a history of drug injection comprise about half of the reported tetanus cases (17). 
Outbreaks of tetanus have been documented in drug user populations, particularly among users who report 
subcutaneous injection of heroin and have a history of no or partial immunisation (18-19). 
The spread of infections that are associated with injecting drug use have been controlled during the last decade in 
some European countries, and infection rates are falling (8). This has most likely been due to a combination of 
behaviour change in user populations, scaling-up of prevention services, and treatment of disease and vaccination. 
Despite these positive developments, there is no room for complacency as blood-borne infections can spread very 
rapidly among people who inject drugs, unless injection-driven infection risks can be continuously controlled. 
Several studies of HIV outbreaks among people who inject drugs document an almost exponential spread in the 
early stages and the rapid establishment of high HIV prevalence levels (20-21). The same has been demonstrated 
for hepatitis C, where a combination of low infection dose, extended length of viral survival outside of the body, 
and continuously high blood virus load in chronic infection may result in very rapid establishment of high 
population prevalence among users. 
Despite the successes in reducing disease prevalence in some regions of the EU, available estimates clearly show 
that infections among people who inject drugs are not yet effectively prevented in all areas of the European 
neighbourhood. Although preventable, these infections continue to cause major disease burden in Europe and high 
levels of personal suffering.  
Not 
included, 
not 
reporting, 
or not 
known
40 < 60%
≥ 60%
0 < 40 %
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Why is this important?  
The main motivation for the prevention of infections among people who inject drugs is that prevention is feasible 
and effective, if properly implemented. Addiction to illicit drugs is a medical condition which, on public health and 
ethical grounds, demands the implementation of effective measures to prevent disease and minimise the harms 
caused by drug addiction. Effective measures to prevent infections exist, but are either not offered or not 
accessible to a high proportion of those in need of them.  
From a public health perspective, subpopulations with a high burden of infections have both a direct and indirect 
burdening effect on society, and the prevention of infections can minimise these costs. Firstly, direct morbidity due 
to severe forms of chronic infections results in high costs of treatment and care among those infected. Secondly, 
the loss of human productivity among the severely affected increases the societal costs. Thirdly, a high prevalence 
of disease among drug users may enhance the risk of increasing prevalence in the wider population, especially if 
high prevalence is maintained for long periods of time.  
Finally, failure to counteract an avoidable consequence of a particular form of severe addiction could be interpreted 
as indifference to the EU’s pledge to promote social justice and protection, as committed to in international 
conventions, including the Charter of Fundamental Rights of the European Union and the Lisbon Treaty (22-23). 
While the elimination of illicit drug use or of drug injecting would, in principle, be a good intervention for infectious 
disease prevention, global experience has shown that this cannot be achieved through public health measures 
alone. Strict drug control measures have not been successful in completely eliminating the risks and illicit drug-
related harm. On the contrary: while clarifying that public health concerns were the driving concern behind drug 
control, an evaluation of a century of international drug control efforts by the UNODC found that the drug control 
system and its applications have had several unintended consequences, including a lack of investment in tackling 
the public health harms of drug use. Drug use is mainly dependent on other societal factors (a review of which is 
beyond the scope of this guidance), and drug use practices are highly dependent on drug user subcultures and 
economic realities, which may be difficult to influence. However, experience and evidence have shown that 
adopting a pragmatic approach which addresses and limits the direct infection risks associated with the injection 
procedure and which introduces measures that help stop or reduce injecting can have a strong effect on reducing 
the spread of blood-borne infections among people who inject drugs. 
Aims, objectives and methodology 
This evidence-based guidance is designed to inform the development, monitoring and evaluation of national 
strategies and programmes in countries in the EU and the European neighbourhood to prevent and treat infections 
among people who inject drugs. The guidance is in coherence with existing EU-policies in the field of drugs and 
infectious diseases (24-27). 
The guidance relies on a foundation of core values described in a separate section below.  
Seven key interventions are identified to reduce and prevent infections among people who inject drugs in Europe. 
These are based on the most robust scientific evidence available, combined with expert opinion and long-standing 
and well-documented experience of service providers and preferences of users of services.  
Two ECDC/EMCDDA Technical Reports provide an overview of the evidence base behind the interventions 
recommended here: ‘Evidence for the effectiveness of interventions to prevent infections among people who inject 
drugs. Part 1: Needle and syringe programmes and other interventions for preventing hepatitis C, HIV and 
injecting risk behaviour’ and ‘Part 2: Drug treatment for preventing hepatitis C, HIV and injecting risk behaviour’. 
Evidence base 
In the process of drawing up this guidance, evidence reviews covering a large number of primary studies on the 
key interventions in question were systematically assessed, using a highly standardised ‘review of reviews’ method1. 
Outcomes of studies using the most robust scientific designs were collated and statements regarding their 
effectiveness were derived, synthesising results in terms of study design, number of cases included in the studies 
and number of studies sharing the same results – factors that determine the strength of the evidence. The 
resulting top-level evidence from this ‘review of reviews’ was combined with the most recent primary research 
results not yet captured by review papers. Primary studies were also used when no systematic reviews about the 
 
                                                                    
 
1 The ‘review of reviews’ methodology (Kelly et al., 2002) brings together evidence from published reviews rather than 
undertaking a systematic search of primary literature. The ‘review of reviews’ methodology involved a systematic search of the 
literature for published reviews; identification of relevant systematic, meta-analytic and narrative reviews; critical appraisal of the 
reviews; and synthesis of the findings. 
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effectiveness of an intervention were available. The methodology used for identifying and selecting the reviews 
and primary studies and results are described in detail in the two technical reports which accompany the guidance.  
However, in the field of public health it is sometimes not possible to obtain the type of strong evidence levels that 
can be derived from experimental studies such as randomised controlled trials (RCTs). Some public health 
interventions can – for ethical reasons – not be tested in an experimental way (by providing them to one group 
and withholding them from another). Also, the control of confounding factors under real-world conditions would be 
very complex and require prohibitively expensive study designs. Another obstacle to the identification of 
statistically significant positive or negative outcomes of interventions in this field is the low incidence of relevant 
outcomes, so that research has to cover a very long period to accumulate a sufficient number of relevant events 
before drawing a conclusion (28).  
The relationship between evidence and recommendations is not necessarily straightforward: high-quality evidence 
does not always lead to strong recommendations, and strong recommendations can arise from low-quality 
evidence. In those instances when review-level evidence on interventions was inconclusive or when there was a 
noted lack of evidence on inventions, this guidance draws instead on expert advice regarding the potential benefits 
and harms of certain interventions, looks at best practices in prevention services in the EU, and assesses studies 
on user preferences. While expert opinion is considered a weaker level of evidence, there are conditions under 
which an expert group may attribute high strength to recommendations in the absence of robust research evidence. 
Examples are hydration of hospital patients or blankets to prevent heat loss in trauma patients – interventions that 
are not based on a strong evidence base from scientific research studies, but are still highly recommended. 
Additional information on the reasoning behind each recommended intervention is available in Annex B.  
Scope  
This guidance builds on previous efforts in the area of infection prevention among people who inject drugs, 
particularly work conducted by the WHO, UNAIDS, and UNODC; in addition, multiple national guidelines and 
recommendations were consulted (see Annex C). The present guidance attempts to give a comprehensive 
overview of the best current knowledge in the field by expanding previous work to include combinations of key 
interventions. Its aim is to provide a thorough synthesis which is not only pertinent for the EU but also for the EU’s 
neighbouring countries. The guidance contains references and links to further sources which provide additional in-
depth information and descriptions of the technical implementation (Annex C). 
This guidance mainly focuses on the interventions and preventive measures that address the infection risks directly. 
The main infections covered are HIV, hepatitis B, hepatitis C, and tuberculosis (TB). Some other infections for 
which people who inject drugs may be at higher risk, such as skin and soft tissue infections, hepatitis A, and 
sexually transmitted infections are discussed, but in less detail. The guidance addresses issues such as knowledge 
and understanding, risks of drug preparation and injection, equipment sharing, vaccinations, drug substitution and 
other forms of drug treatment in order to reduce injection frequency and increase treatment adherence. It also 
suggests ways of organising relevant services in an effective way.  
People who inject drugs addressed in this guidance include opioid and stimulant injectors. While the focus of the 
guidance is on these ‘traditional’ injecting populations, the interventions proposed may also be relevant for new or 
emerging groups of injectors, such as those who inject performance-enhancing drugs like anabolic steroids. 
Observations from some countries suggest that the latter group of injectors may warrant further monitoring. 
Problem drug users who do not inject would likely benefit from many interventions discussed here, although they 
are not the key target for this guidance.  
The guidance does not extensively discuss the use of antiviral treatment as prevention at the population level, but 
it makes clear that such treatment should be equally available and accessible to a person who injects drugs. 
Recently published work suggests that positive effects (reduced transmission) may be significant, providing an 
additional strong rationale for treating active drug users for HIV and hepatitis infections. There is evidence showing 
the beneficial effects of prophylactic TB treatment of those infected with latent TB in reducing population-level TB 
prevalence and incidence. As a consequence, the guidance includes treatment of infections as one of the key 
interventions. 
The guidance document is designed to address the needs of adults who inject drugs. Minors and youths are 
beyond the scope of this guidance. It is nevertheless recognised that in some settings, minors and youths form a 
significant proportion of those who inject drugs. Addressing the needs of minors and youth would require 
customised, age-appropriate services (see text box, page 26).  
From a prevention perspective, it is very important to protect the youngest sub-populations of those who inject 
drugs from chronic blood-borne diseases and TB. Therefore age limits to access services are not considered useful 
and may even be counterproductive as they tend to increase risks for persons who are under the age of legal 
adulthood.  
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This guidance on prevention of infections is mainly aimed at service providers in community settings. However, the 
guidance also has relevance for detention settings.  
According to the principle of ‘equivalence of service provision’, prisoners are entitled to have access to the health 
services available in the country without discrimination, and prison health services are expected to provide 
treatment for problems related to drug use in conditions comparable to those offered outside prison (29-30). 
Prisoners with a history of drug injecting often have multiple and complex health needs, requiring specialist 
medical care and a multi-disciplinary approach. Persons recently released from prisons form an important target 
group for prevention of infectious diseases and should be considered when planning national prevention strategies 
(31). Likewise, the needs of persons entering prisons should be considered (32). 
Target readership  
This guidance aims to support decision makers in prevention programmes at national and regional levels, who 
work in the fields of infectious diseases, general public health, addiction and mental health, social services and 
drug control. It aims to help EU Member States and candidate (and potential candidate) countries in planning 
adequate and evidence-based, rationally designed public health responses to injecting drug use. The guidance 
identifies good EU practices for the prevention and control of infectious diseases among people who inject drugs. It 
is hoped that EU partnership countries may find the guidance useful and relevant. The guidance is not presented 
at a level of detail that prescribes the technical aspects of implementation, and it is up to implementing services to 
adapt the suggested intervention and prevention options to local and national circumstances. Despite this, the 
guidance may be of interest to managers of local services, as its aim is to comprehensively list and explain all 
components which should be part of a systematic approach to the prevention of key infectious diseases among 
people who inject drugs. 
  
 
 
 
 
ECDC AND EMCDDA GUIDANCE Prevention and control of infectious diseases among people who inject drugs 
 
 
 
9 
 
 
 
 
Core values of prevention of infections 
among people who inject drugs 
The core values presented in this section are based on fundamental principles of public health, service provision, 
individual and public health ethics, combined with substantial experience in service implementation. They were 
developed by ECDC and the EMCDDA and are supported and endorsed by the ECDC/EMCDDA Technical Advisory 
Group. The core values were developed with a public health and human rights perspective and originate from work 
based in the United Kingdom and the Netherlands in the 1980s (the ‘Mersey Harm Reduction Model’, a population-
based service model) (33-34). They focus on people who inject drugs and aim to reduce the negative 
consequences of drug use (35-36). The core values should be seen as the foundation of effective key interventions, 
as presented in this guidance. When developing services, planned interventions should conform to the core values. 
In this guidance, the core values are presented in two subsections, ‘principles of prevention’ and ‘principles of 
service provision’.  
Figure 3: Core values of prevention of infections among people who inject drugs 
 
Principles of prevention 
This guidance is based on four simple principles: a pragmatic approach to health promotion, a clients’ rights 
perspective based on basic ethical principles, the resolve to achieve public health objectives, and scientific evidence 
combined with expert experience. The guidance does not work from the assumption that sobriety or abstinence is 
the ultimate goal of all drug-related public health policies (33,35,37-38). On the other hand, this guidance is 
neither incompatible with an abstinence framework nor does it explicitly exclude such a framework. It does not 
discuss drug control polices but restricts itself to address the immediate individual and societal harm caused by 
infections among people who inject drugs. The key interventions suggested in this guidance would be difficult to 
apply effectively if they were not built upon the following prevention principles: 
‘A pragmatic approach to health promotion’ in this context means that rather than working from a hierarchy 
of goals within a full range of drug policies, this guidance – and the measures discussed in it – primarily address 
the spread of infections among injecting drug users and how the high risk of infection in this group could be 
curbed. Therefore, the approach makes no a priori assumptions on how prevention measures should be 
implemented, but argues for the independent public and individual health value of such measures. To be free of 
drugs should not be a condition for receiving help to prevent infections. Instead of a dogmatic approach in which 
the goal of preventing drug use overshadows other objectives, the pragmatic approach recognises that any health 
benefit has a value of its own and is worth pursuing, even when the underlying drug use may not be immediately 
• Ensure confidentiality.
• Promote service accessibility.
• Create a user-friendly atmosphere.
• Engage in dialogue with users and 
promote peer involvement.
• Adopt a practical approach to the 
provision of services.
• Refrain from ideological and moral 
judgement.
• Maintain a realistic hierarchy of goals. 
A pragmatic approach to health 
promotion
The clients’ rights perspective
Public health objectives Guidance based on scientific 
evidence and expert experience
Principles of prevention
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addressed (37). All users may not become drug-free, but risky injection practices and disease transmission can be 
prevented.  
‘The clients’ rights perspective’ in the context of this guidance means that the measures taken for prevention 
and intervention strictly adhere to the principle of using the client perspective. Prevention measures are developed 
first, based on the individual client’s needs, and provider or societal needs are only addressed after the client's 
needs have been met. Also, all measures are provided to the client on a voluntary basis and no coercive or 
mandatory components should be used. Furthermore, access to prevention is seen as a personal right, not a 
benefit. Lastly, preventive measures should always benefit the individual and not only society (35,39). 
‘Public health objectives’ in the context of this guidance means that although the benefits of the intervention 
methods should first address individual needs, the comprehensive approach should always strive to achieve 
societal as well as individual benefits. Intervention methods should include prevention of further transmission, 
reduction of total healthcare and social costs, improved productivity and reduced mortality and morbidity among 
the target group, including prevention of drug use, whenever compatible with the primary objectives (40). 
‘Guidance based on scientific evidence and expert experience’ means that this guidance is based on 
scientific evidence in as far as robust studies for the discussed measures exist. For some of the recommended 
measures, robust studies demonstrating their efficacy have not been performed, either due to the complexity of 
the design requirements or due to ethical problems in conducting the studies (41-42). In some cases, the best 
available evidence comes from published ecological or descriptive studies, or has been captured by the experience 
and advice of the technical experts participating in the production of this guidance. Some measures in the 
guidance are recommended because their application is logical and considered to benefit the individual without 
incurring any undue risk, i.e. applying these measures makes sense from a pragmatic point of view.  
Principles of service provision 
In addition to the principles of prevention discussed above, the implementation of preventive measures in this 
guidance should adhere to the following core principles which all are derived from the need to adopt a client 
perspective in service provision (43). Without the application of these core principles, it is difficult to effectively 
apply the key interventions suggested in this guidance:  
• Ensure confidentiality. 
• Promote service accessibility. 
• Create a user-friendly atmosphere. 
• Engage in dialogue with users and promote peer involvement. 
• Adopt a practical approach to the provision of services. 
• Refrain from ideological and moral judgement. 
• Maintain a realistic hierarchy of goals.  
Obtaining the trust of the clients of the services is essential for the prevention of infectious diseases. As drug use 
and the possession of illicit drugs is criminalised in many countries, users are reluctant to reveal their identity even 
to health professionals for fear of becoming known to law enforcement or other authorities (44-45). This fear must 
be overcome so that clients can be attracted to health services. Being required to present full identification, often a 
standard practice for health service provision, will deter many users from obtaining services.  
Ensure confidentiality. The first core principle means that it must be possible to access the preventive service 
anonymously or in a way that ensures full confidentiality, as seen from the client’s perspective. Failure to do so will 
prevent or limit the client’s use of the offered services and thus compromise any effects of ‘herd immunity’, which 
boost prevention at the population level (46-47). To ensure confidentiality, training in providing confidential 
services should be given to all staff. For the provision of certain services, such as testing, vaccinations and 
sometimes drug dependence treatment, a strictly confidential identification scheme may be necessary, which is 
usually acceptable to service users. Approaches to monitor service provision to acceptable levels of accuracy 
without compromising anonymity and confidentiality have been developed (48)2.  
Promote service accessibility. The second core principle ensures that services can be easily reached by people 
who inject drugs and that a low threshold of access is achieved. This means that services must be located where 
the users are, or where they can easily get to. Services need to be available at varying times of the day (46,49-52). 
Services should meet demand and be scalable, so that all in need can be offered appropriate, relevant and 
sufficient services (20,53).  
 
                                                                    
 
2 In service settings, a variety of approaches have been developed, including the use of nicknames, anonymous identification 
cards, or codes to track service use while maximising confidentiality. 
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Create a user-friendly atmosphere. A third core principle of service provision is the need to maintain a user-
friendly atmosphere. This principle may seem intuitively self-evident, but its implementation is a key element in 
ensuring client uptake of services. A user-friendly atmosphere means that clients are addressed with dignity and a 
true willingness to help, whatever their appearance or social status. It also means that client wishes are respected, 
and services are not forced on them (50,52). It does not mean that clients can behave as they please, particularly 
if their behaviour creates disturbance or danger to others. On the contrary, service providers should develop and 
communicate clear rules of conduct for the service premises. Most services do not allow illicit drug dealing, 
financial transactions or injecting at the premises, and breaking of these rules can lead to a temporary ban from 
services (43). Many users suffer not only from drug addiction but also from mental health disorders (54). Such 
users are frequently the most marginalised and at a particularly high risk of infections. These users should not be 
labelled as ‘too difficult’ or ‘too challenging’ but services need to develop ways of working with them in a humane 
and respectful way.  
Engage in dialogue with users and promote peer involvement. Conducting a dialogue and engaging clients 
actively in the work should be an integral part of the offered services. Actively listening to the clients and 
responding to changing needs in cooperation with the users helps to maintain the relevance of the services (55). 
Injecting rituals and habits are often passed on from more experienced users to novices (56). Secondary exchange 
of syringes, where syringes are distributed from one user to his or her peer network, is common (48,57-58). 
Prevention professionals need be up-to-date on current drug use patterns, and users need to understand the 
health risks attached to these. Service providers can also arrange risk management and health promotion training 
for active users and encourage the participants to disseminate this information. This not only improves the 
usefulness of the services, but also empowers the users (59-60). Experience shows that involving active users in 
prevention work creates positive peer pressure, as clients learn safer drug delivery methods from each other (61-
63). The main challenge among service providers is to acknowledge and embrace the cooperation with users.  
Adopt a practical approach to the provision of services. The fifth core principle also takes the client 
perspective: services are built from the ground up, based on current needs and with the aim of closing gaps in 
prevention services that create infection risks and accurately addressing the health needs of the users (64). It also 
means recognising that even if all drug-related harm cannot be immediately addressed, there is value in every 
intervention as long as it responds to a true need (43). This is different from an ideological or top-down approach 
where the aims may be set so high that they may remain unreachable to the individual user, the service providers 
and the policy-setters. 
Refrain from ideological or moral judgment. The sixth core principle recognises that services are provided to 
active drug users, and it is not helpful to judge or criticise the use itself from a moral or ideological point of view 
(65-66). Instead, the choices users make should be respected even if they are not agreed with and service 
personnel should be actively coached to demonstrate this respect (67). This does not mean that referral to 
addiction treatment services should not be offered. On the contrary, the threshold for this should be low, and 
information on avenues of access should be available at all premises that service drug users frequent (43,53,68).  
Maintain a realistic hierarchy of goals. The final core principle advocates that short-term goals be set so that 
they can be realistically achieved. This approach can help to develop targets for service delivery (43). Setting 
prevention goals too high is frequently unrealistic and may lead to unnecessary disappointment and incorrect 
conclusions on the effects of interventions (69). The basic hierarchy of the goals of the services may vary 
according to local needs and situations, but should include goals such as reaching the majority of user groups, 
establishing trust with clients, responding to the practical needs of users, diminishing the immediate infectious 
disease risks, and increasing service volume over time.  
The overarching goals of disease prevention such as protection from outbreaks and reduction of disease incidence 
and prevalence should be set at the programme level; they should also be adjusted to the current situation and 
realistic in their targets (53). Such goals are usually not useful as impact indicators for individual prevention 
services and should only be used for national-level benchmarking if there is a very good coverage of target 
populations and a comprehensive service package. It is important to recognise that especially if the prevalence of 
chronic infections has reached high levels, a long-term perspective to prevention has to be adopted, as disease 
indicators will improve slowly over time. Services need to be scaled up, and sufficient time needs to pass before 
effects become measurable (see section on ‘Setting targets for intervention coverage’, page 33). 
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Recommended interventions for the 
prevention of infections among people who 
inject drugs 
The components listed in this chapter are recommended to be included in national comprehensive programmes 
which have the objective of effectively preventing and reducing infections among people who inject drugs. 
Key intervention components  
Based on the most robust evidence available, expert opinion, and best practice used within the EU/EEA, the 
following key intervention components should be applied and, if possible, be combined to achieve the maximum 
prevention effect through synergy.  
• Injection equipment: Provision of, and legal access to, clean drug injection equipment 3, including 
sufficient supply of sterile needles and syringes, free of charge, as part of a combined multi-component 
approach, implemented through harm-reduction, counselling and treatment programmes.  
• Vaccination: Hepatitis A and B, tetanus, influenza vaccines, and, in particular for HIV-positive individuals, 
pneumococcal vaccine 
• Drug dependence treatment: Opioid substitution treatment and other effective forms of drug 
dependence treatment  
• Testing: Voluntary and confidential testing with informed consent for HIV, hepatitis C (hepatitis B for 
unvaccinated) and other infections including TB should be routinely offered and linked to referral to 
treatment. 
• Infectious disease treatment: Antiviral treatment based on clinical indications for those who are HIV, 
HBV or HCV infected. Anti-tuberculosis treatment for active TB cases. TB prophylactic therapy should be 
considered for latent TB cases. Treatment for other infectious diseases should be offered as clinically 
indicated. 
• Health promotion: Health promotion focused on safer injecting behaviour; sexual health, including 
condom use; and disease prevention, testing and treatment.  
• Targeted delivery of services: Services should be organised and delivered according to user needs and 
local conditions; this includes the provision of services through outreach and fixed site settings, offering 
drug treatment, harm reduction, counselling and testing, and referrals to general primary health and 
specialist medical services.  
 
                                                                    
 
3 In addition to needles and syringes, drug injection equipment includes cookers/spoons or drug mixing containers, filters, 
acidifiers, sterile water, dry swabs and alcohol swabs. See text box on page 16 for more details on drug injection equipment. 
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Combine key interventions to achieve synergy 
The combined effect of multiple interventions show a drastically reduced incidence of HCV and HIV infection; self-
reported injecting risk behaviour was also significantly reduced (70) (71-72).  
 
  
Combination interventions 
Whenever possible, interventions should be combined to achieve synergistic effects. Evidence suggests that the 
biggest reduction of HIV, HCV and injection risk behaviour can be achieved by providing both high coverage of 
needle and syringe programmes and opioid substitution treatment. It is likely that additional services, such as 
disease treatment and vaccination, offered in combination with needle and syringe programmes and drug 
dependence treatment, would still further prevent disease transmission among people who inject drugs. 
While there is sufficient evidence on the positive effects of combining opiate substitution therapy and the 
provision of needles and syringes, it stands to reason that other interventions which have been shown to be 
beneficial would also lead to synergistic prevention effects when provided in combination with other 
interventions. The adherence to treatment for infectious disease, such as HIV, is known to improve when 
combined with drug dependence treatment (1-2). Some of the effects of the provision of combined services 
may be direct while some may be indirect through attracting and attaching clients to services, which improves 
service reach and coverage. 
Strong collaboration between sectors is crucial as a prerequisite for service provision and in order to ensure the 
delivery of these key interventions. This aspect is discussed more thoroughly in the sections below. 
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Developing and providing programmes for 
infectious disease prevention and control 
among people who inject drugs 
Effective delivery of key interventions can only be achieved through national and local cooperation and 
coordination between sectors.  
Cooperation and coordination 
National consensus building and mutually respected objectives that have been agreed on across all sectors by 
actors that engage with people who inject drugs are needed to effectively prevent spread of disease. Actors in 
infectious disease control, addiction medicine, mental health, social services, law enforcement, judiciary sectors, 
and narcotics control agencies as well as prison services are of national relevance and should be engaged and 
active in this process. In addition, local governments, citizen groups, associations for people who use drugs, as 
well as a multitude of other non-governmental or civil society organisations are relevant to include in coordination. 
Drug use remains a crime or offence in a majority of European countries. Therefore, not only issues of health 
should be considered when prevention programmes are designed, but issues of law enforcement also have to be 
taken into account. 
Similarly, people who inject drugs are frequently affected by social problems and mental illness, which increases 
the challenge of coordination of responses. As some services will have to be provided through referrals, links to 
health and social services need to be established and maintained.  
A ‘buy-in’ from each of these actors is required if effective prevention results are to be achieved. For example, it is 
important to ensure the collaboration of law enforcement services to clarify that the provision of drug injection 
equipment is a public health measure, and that law enforcement should not interfere with the operation of needle 
and syringe programmes or outreach workers. Raids by law enforcement in the vicinity of service sites effectively 
undermine any chance of achieving the objectives of prevention services by scaring off potential clients. Law-
enforcement policies are usually centrally determined and the strict, top-down leadership style that is common in 
most countries prevents deviations from local policy. This must be taken into account, and top-level cooperation 
agreements can help facilitate local-level collaboration in most settings.  
It is therefore necessary to gain support for prevention activities not only from local actors and from the health 
branch of administration, but across all relevant central administrative branches, including law enforcement. This 
frequently requires top-level agreements or at least respect for the goals of the services, which is also clearly 
communicated down to the actor or service provision level.  
Cooperation with local governments is also important. Service site establishment often is opposed by ‘not in my 
backyard’-reactions among local residents fearing detrimental effects to the local environment. Strong leadership 
and community engagement is therefore required by local actors combined with a clear justification of documented 
local benefits such as the reduced littering of drug injection equipment (73).  
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Seven recommended key interventions  
Injection equipment  
 
The main risk factor for acquiring blood-borne infections is the sharing of needles, syringes, and other drug 
preparation and injection equipment. Even among those people who report never sharing needles and syringes, it 
is common to share drug preparation equipment such as drug mixing containers, water for dissolving drugs, or 
drug filters, which could result in the transmission of hepatitis C or bacterial infections (74-75) (see text box on the 
spread of infection through drug preparation equipment, page 16). There is also evidence that people who inject 
drugs suffer from a large burden of skin, vein and blood infections due to non-sterile injection practices (17). There 
are reports of increased injection of prescription drugs crushed up from pill into powder form, which increases the 
risk for pulmonary emboli and endocarditis (76-78). Some homemade acidifiers, used to make certain drugs 
soluble, have been shown to harbour fungus which, when injected, can cause the heart infection endocarditis or an 
infection of the eyes which can lead to blindness called candidal endopthalmitis (79).  
Considered judgement: Based on existing evidence, expert opinion and safe injection practice (80), the best way to 
minimise the spread of HIV and HCV among people who continue to inject drugs is to provide sterile needles and 
syringes and other clean injecting equipment (spoons/cookers, filters, water for injection, acidifiers, and dry and 
alcohol swabs) for each injection and in sufficient quantities. Provision should ideally be free of charge and 
organised through a mode of distribution that is acceptable and easily accessible to users.  
Practice considerations: While some settings require the return of used needles and syringes in order to be given 
new ones, this policy can be counterproductive and act as a barrier to accessing and using sterile injection 
equipment. In order to achieve the goal of infectious disease prevention, easy access to needles and syringes 
should be promoted and the return of needles and syringes should be encouraged, but not absolutely required, in 
order to receive new supplies. The risk of needle stick injuries en route to the disposal site and for staff at the NSP 
has to be considered carefully. To encourage safe transportation and disposal of injection equipment, it is 
recommended to provide puncture-proof containers to collect and return injection equipment. Other strategies 
such as community-based safe disposal sites or home collection have also been successfully used in some settings. 
Coordination between needle and syringe exchange services and the police is essential to assure that carrying 
injection equipment will not be used as a reason for arresting drug users in the vicinity of NSPs. 
Clients usually express a preferences for syringe types and needle sizes; this varies vary by setting and user sub-
group. These preferences should be carefully considered in order to maximise service uptake. In some settings, for 
example, retractable needle-syringe combinations have been provided, where the needle retracts into the syringe 
after use, preventing re-use. However, clients in some settings found these unacceptable, which led to limited 
service uptake and retention. User-friendliness, acceptability and promotion of service uptake should be the main 
criteria for decisions on the type and variety of syringes and needles offered. Clients’ views and preferences should 
also be taken into account regarding drug preparation equipment and the type and size of puncture-proof 
containers for storage of used needles and syringes, as these preferences will also vary by user sub-group. 
There is evidence from systematic reviews that the provision of needles and syringes leads to significant reductions 
in self-reported injection risk behaviour (81). There is also evidence that needle and syringe programmes may 
reduce the prevalence of HIV (81) (82). Due to methodological limitations, it has been more difficult to conclusively 
study the link between the provision of drug preparation equipment, such as drug mixing containers, sterile water, 
and cotton filters, and reductions in HCV or HIV (83). However, HCV could be isolated from 67% of swabs, 40% of 
filters, 33% of water samples, and 25% of spoons that were used by HCV-positive individuals to prepare drugs for 
injection (84).  
There is epidemiological evidence from primary studies that sharing drug preparation equipment, particularly drug 
cookers, is associated with HCV transmission among injectors who do not share needles or syringes (85) (75).  
Recommended intervention 
Provision of, and legal access to, clean drug injection equipment, including sufficient supply of 
sterile needles and syringes free of charge, as part of a combined multi-component approach, 
implemented through harm-reduction, counselling and treatment programmes. 
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There is a lack of strong research evidence on the effectiveness of distributing injection preparation equipment 
such as sterile water, spoons/cookers, filters or alcohol swabs in reducing the incidence of HIV and HCV. One 
primary study suggests a relationship between sharing drug preparation or injection equipment and self-reported 
positive HCV status (86). There is also a risk of bacterial skin infections due to the reuse of injection equipment or 
unhygienic injection practices (17). However, there is evidence that the distribution of such equipment reduces 
injecting risk behaviour (87) (88) and acts as an incentive to attract and retain clients to services (89). Supply of 
citric acid sachets to people who inject drugs in one UK setting was found to be very well-received by clients, and 
helped to attract clients to needle and syringe services (90).  
Sterile needles and syringes, as well as clean injection equipment should be provided along with health promotion 
messages about drug treatment services and information on the warning signs of soft tissue or skin infections (for 
additional information on health promotion messages for people who inject drugs see the box on health promotion, 
page 24). Attention should be paid to giving information about safe injection practices, which stress that each 
needle and syringe, as well as the equipment for the preparation of drugs for injection (cookers or mixing 
containers, cotton filters, water) should all be single-use and never shared among injecting partners. It may also 
be worth considering the provision of equally attractive non-injecting equipment, such as foil for heroin users or 
gelatine capsules for amphetamine users, which promote non-injecting routes of drug use (91-92).  
Health promotion information should stress the washing of hands with soap and clean water and the cleansing of 
the injection site with an alcohol swab (or soap and clean water) prior to injecting. Dry cotton swabs, rather than 
the used alcohol swab, should be recommended to cover the injection site immediately after injection. Information 
should be given about early signs of skin infections or abscesses and phlebitis, and users experiencing such 
symptoms should be encouraged to seek early medical care.  
Despite strong advice that needles and syringes, as well as drug preparation equipment, should not be shared or 
re-used, there is evidence in most settings that re-use does occur, often unintentionally. The first response to re-
use should be to increase the availability and accessibility of needles, syringes, and drug preparation equipment so 
that a new set can be used for each injection. If this is not possible, there are two ways in which to assist people 
who inject drugs to minimise the harms which could result from the re-use of needles and syringes. First, syringes 
that come with numbers, colour codes, stickers, or some other system of anonymous identification can help to 
create a marker system to minimise inadvertent sharing of syringes. Second, while the use of chlorine bleach for 
the disinfection of injecting equipment is controversial, it might be considered in cases where known re-use is 
occurring. Although the efficacy of bleach in inactivating HIV in a laboratory setting has been demonstrated (93), 
there is insufficient evidence of its effectiveness in injection practice because disinfection protocols are not 
necessarily strictly adhered to. Providing bleach may be a ‘second-line’ alternative to providing sterile injection 
equipment, but providing sterile injection equipment is by far the preferred option. 
Spread of infection through drug preparation equipment 
Water: Water is used to dissolve drugs prior to injecting and to rinse and flush the needle and syringe after 
injecting. Users may share a common source of water for this purpose, which potentially puts them at risk of 
contracting blood-borne viruses which may contaminate the water.  
Spoons: Spoons or so-called ‘cookers’ (e.g. Stéricups®) are used to heat and dissolve drugs such as heroin 
prior to injecting or to mix crushed tablets with water. Users may share spoons for drug preparation and 
contact with re-used or contaminated water, or filters may spread bacterial or blood-borne viruses. 
Acidifiers: Acidifiers are used to make insoluble drugs such as brown heroin or crack soluble. Some acidifiers 
may lead to bacterial and fungal infections. Infections can be avoided if single-use sachets of acidifiers, such as 
ascorbic acid, are provided to people who inject insoluble drugs.  
Filters: Dissolved drugs are drawn into the syringe through a filter to prevent large particles from entering the 
bloodstream. Using a filter when injecting into the vein is important as it can prevent blood clots or emboli. 
However, sharing filters may lead to the transmission of blood-borne viruses. Filters tend to be re-used because 
they are thought to contain residual drugs, but some newer commercial filters are designed to minimise drug 
absorption and to dissolve after use. 
Alcohol swabs and dry swabs: Alcohol pads should be used to clean the injection site before injecting. Clean 
dry swabs can be used after the injection to stop the bleeding, as alcohol pads will prolong the bleeding time.  
It is recommended to provide water, spoons, acidifiers and filters, alcohol pads and dry swabs to reduce 
sharing or re-use and to minimise the potential risk for the transmission of blood-borne viruses and bacteria. 
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Vaccination 
 
Considered judgement: Based on existing evidence, vaccination is among the most effective prevention 
interventions available. In most settings, people who inject drugs are at increased risk of acquiring hepatitis B, 
hepatitis A and the bacterial infection tetanus. Persons infected with hepatitis C (for which no vaccine currently 
exists) and who are co-infected with hepatitis A or B suffer from accelerated progression of hepatitis C disease and 
much higher morbidity. Due to lifestyle, age, or HIV infection, some people who inject drugs might be at greater 
risk for influenza or pneumonia. However, effective vaccines are available which can prevent each of these 
infections by providing good clinical protection (94). 
Practice considerations: Hepatitis B vaccination is now included in routine childhood vaccination programmes in 
most Member States, however since this policy was started in the 1990s, some adults who inject drugs were not 
vaccinated in childhood. Although 18 of 29 EU/EEA countries have hepatitis B vaccination programmes for adults 
who inject drugs, this vaccination is not always provided for free (8) (95).  
Because some populations that inject drugs are ‘hard to reach’ for vaccination through traditional means, there is a 
unique opportunity to provide routine or ‘one-off’ vaccination services through fixed sites or mobile services which 
serve people who inject drugs. There is evidence that uptake of vaccination improves when integrated into other 
services (96). Vaccination of people who inject drugs has been found to be cost-saving when conducted at needle 
and syringe programmes, and there have been encouraging results from research on contingency management, 
which has been found to double hepatitis B vaccination completion rates (97-98). Additionally, outreach 
programmes might be an effective way to increase the uptake of repeat doses, while vaccination programmes 
offered in prison settings or residential drug rehabilitation centres can be effective in reaching those who are 
imprisoned or in drug treatment, including people who inject drugs.  
The hepatitis B vaccine is typically administered as three separate injections, given over the course of a six month 
period, although an accelerated dosing schedule is possible. While it might be difficult to ensure that the client 
returns for doses two and three of the vaccine, it is still worthwhile to vaccinate a client who seeks a first dose, as 
even one dose of the hepatitis B vaccine may provide partial immunity (99). It is of note that the self-reported 
vaccination status of people who inject drugs is often inaccurate when compared with their actual serological 
status (100). Testing for hepatitis B serum markers at the first service contact can detect people who incorrectly 
reported hepatitis B vaccinations. Also, the rate of low- or non-responders among people who inject drugs is higher 
than in the general population (101).  
Because of the possibility of a higher risk of hepatitis A outbreaks among people who inject drugs, the provision of 
a combined hepatitis A and B vaccination is suggested as the best way to prevent both infections in people who 
inject drugs (102-103). This is particularly crucial for those who are hepatitis C positive.  
In all European countries tetanus vaccination are given as a part of childhood immunisation programmes, but a 
booster is typically given each five to ten years in adulthood. Tetanus vaccination status should be checked among 
people who inject drugs, and a booster vaccine should be offered if vaccination status is uncertain, particularly for 
those users who have injection site infections. Often the combined tetanus-diphtheria vaccination is given, and this 
is advisable because diphtheria, while rare in Europe, has a high case-fatality rate.  
Finally, it is recommended to provide seasonal influenza vaccination and pneumococcal vaccination (particularly if 
the client is HIV positive and/or more than 50 years of age) in order to minimise the risk of influenza or 
pneumococcal infection (for more information see (16)).  
It is important to note that vaccination against TB using the Bacillus Calmette-Guérin (BCG) vaccine is usually only 
recommended for infants living in areas where TB is highly endemic and for infants or children at particular risk of 
TB exposure in otherwise low-incidence areas. There is limited evidence for the use of BCG in adult patients, and it 
is contraindicated in individuals with impaired immunity such as symptomatic HIV infection (104). 
  
Recommended intervention 
Vaccination with hepatitis B and A, tetanus, and influenza vaccines, and, in particular for HIV-
infected individuals, the pneumococcal vaccine. 
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Drug dependence treatment 
 
Drug dependence treatment represents an important component in a comprehensive response to prevent health-
related harm associated with drug dependence (27,105-106). In many European countries, drug dependence 
treatment forms the centrepiece among a range of interventions to prevent the transmission of drug-related 
infections (54). It also plays a role in increased adherence to infectious disease treatment among people who use 
drugs (1-2,107-108). Drug treatment encompasses a range of medical (including pharmacological), psychological, 
social and behavioural strategies to stop or reduce drug use and injecting, and can be delivered in outpatient or in 
residential settings. Psychosocial therapeutic approaches can vary from individual counselling and motivational 
interviewing techniques to more structured psychological treatment interventions, matched to the individual’s need 
and situation. Important current therapeutic approaches are cognitive and behavioural therapies, which aim to 
influence cognitions and unlearn conditioned drug use behaviour and their various combinations. Psychosocial 
interventions can be used alone or in combination with pharmacotherapy. 
Pharmacological maintenance treatment for opioid dependence consists of the prolonged use of a prescribed opioid 
medication which prevents withdrawal symptoms and reduces craving, thereby allowing the user to lead a more 
stable life; reduce illicit heroin use, risk behaviour, and criminal activity; and improve health, well-being, and 
quality of life (68). Opioid substitution treatment (OST) is often provided in combination with psychosocial 
treatment and further support services (109-112).  
Opioid agonists can also be used for detoxification treatment. However, inpatient detoxification should be 
integrated with other treatment options rather than being provided as a stand-alone service in order to avoid high 
relapse rates (111).  
Effectiveness of opioid substitution treatment  
Data from treatment outcome studies and controlled trials demonstrate the effectiveness of methadone and other 
drug substitution treatments in treating dependence on heroin and other opioids. A large body of evidence from 
reviews exists regarding the impact of OST on the incidence of infections as well as of injecting risk behaviour (81, 
108-111,113-118).  
With regard to risk behaviour, multiple studies with robust study designs that provide evidence for the 
effectiveness of OST in reducing risk behaviour were identified in three major reviews (108,115,118). All three 
reviews concluded that OST was associated with reductions in self-reported prevalence and frequency of injecting, 
in sharing of injecting equipment and injecting risk behaviour scores. 
Assessing the evidence on the effectiveness of OST in reducing HIV transmission, the same reviews consistently 
found sufficient evidence to conclude that OST in community settings is effective in reducing HIV seroconversion, 
especially among those in continuous treatment and when dosages are adequate. 
The evidence for the effect of OST on reducing HCV incidence has been harder to determine. This may largely be 
due to the fact that HCV is more easily transmitted through injecting and, probably, shared injecting equipment4, 
and to the much higher baseline prevalence levels among populations of people who inject drugs across Europe, 
constituting a reservoir of infection risk. However, recent data including community-based cohort studies of 
hepatitis C incidence among clients in OST, together with a meta-analysis of UK-based studies (70-71,119-121) 
suggest a strong positive impact of OST on preventing HCV infections. These studies point to higher benefits 
among those in continuous OST compared to those with interrupted OST; to a protective effect of methadone 
maintenance treatment against both primary5 and secondary6 HIV and HCV infection; and to ‘dose-response’ 
effects of OST, with those in treatment longer having lower HCV incidence rates.  
A number of randomised controlled trials over the past 15 years have provided evidence of the efficacy of 
supervised injectable heroin-assisted treatment (HAT) for long-term refractory heroin dependent individuals, who 
 
                                                                    
 
4 Hepatitis C infection is characterised by comparatively high concentrations of infectious virus in the blood circulation, not only 
during the primary infection phase but also in those individuals that become chronically infected (compared to HIV infection). 
This may lead to high HCV transmission rates upon exposure, as the minimum infectious dose is likely to often be exceeded in 
sharing situations among infected and non-infected people who inject drugs. This hypothesis is supported by the fact that 
hepatitis C prevalence often exceeds HIV prevalence in user communities, and hepatitis C epidemics usually precede HIV 
epidemics in the user communities. It may also explain why it is more difficult to curb the risk of HCV by single interventions 
alone and why higher coverage rates may be needed to reach an effect at population level.  
5 Infection in non-infected individuals. 
6 Infection with HIV or HCV in mono-infected individuals. 
Recommended intervention 
Opioid substitution treatment and other forms of effective drug dependence treatment. 
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do not respond to standard treatments. The results show that when compared to classical or optimised OST, 
treatment-refractory clients in HAT show similar or greater treatment retention, major disengagement from 
criminal activities (such as acquisitive crime to fund continued use of street heroin and other street drugs) and 
achieve major reductions in the extent of injecting of street heroin which are sustained over time (122).  
Considered judgment: Based on consistent evidence from multiple robust studies and reviews as well as expert 
opinion, drug dependence treatment should be available and easily accessible, in particular OST for opioid users. 
Psychosocial treatment enhances the effectiveness of OST when used in combination, is a main treatment option 
for stimulant users, and is recommended based on expert opinion. 
Combination approaches enhance the impact of OST on infections 
Studies on compliance, completion of treatment and abstinence outcomes at follow-up confirm that the 
effectiveness of OST can be improved when psychosocial interventions are also provided (123). In a randomised 
controlled study of the effect of behavioural interventions on HCV incidence among people who inject drugs in the 
UK (124), enhanced preventive counselling combined with OST was compared with OST alone. The results showed 
lower rates of HCV sero-conversion among the group receiving both interventions. 
Recent research points to the importance of combining opioid substitution treatment with further harm reduction 
measures in order to reduce the incidence of infections, including HCV transmission. The Amsterdam cohort study 
(71) found that full participation in both methadone maintenance treatment and needle and syringe programmes 
over a six-month period was associated with a lower risk of HCV infection, albeit the effect could not be shown for 
methadone maintenance or needle and syringe programmes alone. A UK-based cohort study (119) also noted a 
greater impact of OST on reducing HCV incidence when combined with syringe provision. Most recently, a meta-
analysis of six UK-based studies that collected individual-level data on intervention coverage as well as newly 
acquired HCV infection amongst people who inject drugs in the community documented that providing OST and 
needle and syringe programmes independently reduced HCV incidence rates among this group (70). In addition, 
the two interventions acted synergistically, reducing the odds of new HCV infection by nearly 80% when a high 
coverage of needle and syringe programmes was provided for those who continued to inject while on opioid 
substitution treatment.  
The effectiveness of combination approaches on HIV transmission was further assessed in a study carried out in 
New York City (125), comparing the effectiveness of a ‘combined prevention program’ (methadone maintenance, 
education and outreach, risk reduction, HIV testing and needle and syringe programme) with an ‘initial prevention 
program’ excluding needle exchange (methadone maintenance, education and outreach, risk reduction, HIV 
testing). Over time, the observed HIV prevalence increased to a greater extent among those on the limited 
programme compared to those on the combined programme, which suggests that the combination of OST with 
syringe exchange may have played a role in limiting HIV transmission. 
Effectiveness of other treatment approaches 
There are a number of other drug treatment options available, including psychosocial treatment, cognitive 
behavioural interventions, contingency management, and peer-based support groups.  
While no psychosocial treatment intervention alone has been shown to be clearly effective in treating opioid 
dependence (108), findings from observational studies (large cohort studies such as DATOS in the US and NTORS 
in the UK) show that residential, community, and methadone maintenance treatment programmes all reduced both 
injecting drug use and needle sharing. While in treatment, injecting and risk behaviours are reduced and 
consequently the risk of infections is lower (109). Psychosocial treatment can play a major role in addressing co-
morbid psychological disorders of drug users, like anxiety, depression or low self-esteem, and in improving drug 
use-related coping skills.  
Treatment for non-opioid dependent people who inject drugs 
Although some pharmacological agents for the treatment of stimulant users have been found promising or are 
currently being tested, no pharmacological treatments have yet been found to be consistently efficacious in 
reducing drug use and increasing treatment retention for this group (108). Several randomised trials are underway 
to test new drugs for the treatment of cocaine dependence; at present, Disulfiram, a substance that interferes with 
the metabolism of alcohol, and Vigabatrin, an anti-epilectic drug are two substances that show some promise. 
Attempts to develop a cocaine vaccine are continuing (54). 
In the absence of pharmacological treatments, psychosocial treatment is especially important for stimulant users. 
However, the only systematic review of the evidence regarding psychosocial treatment for psychostimulant abuse 
or dependence did not draw firm conclusions regarding the effectiveness of a single treatment approach in relation 
to psychostimulant dependence, owing to the heterogeneity of studies (126).  
One major review found that contingency management (CM), which includes providing monetary incentives for 
remaining drug-free or in treatment, was associated with higher rates of abstinence and retention in treatment for 
stimulant users (108). If combined with methadone maintenance, CM showed positive outcomes for clients 
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dependent on both opioids and stimulants. However there is still a relative lack of evidence to consolidate these 
findings.  
The same review highlighted that there is modest evidence of efficacy of other behavioural approaches, including 
cognitive behavioural therapy, community reinforcement with CM, and individual counselling to address stimulant 
abuse. There is weak evidence regarding the impact of motivational interviewing and for the effectiveness of 
therapeutic communities with regard to the treatment of stimulant users.  
Providing opioid substitution treatment  
Methadone maintenance treatment was developed in the USA in the 1960s, but its introduction in clinical practice 
in Europe increased only from the mid-1980s onwards. Today, methadone and buprenorphine, dihydrocodein, 
slow-release morphine, and diacetylmorphine (heroin) are in use in European countries7 (112). Following the 
adoption of comprehensive drug policies by EU countries, the provision of opioid substitution treatments 
accelerated since the mid-1990s and reaches now more than half of the estimated target population (54,127-128). 
The share of buprenorphine in opioid substitution treatments in Europe is smaller than that of methadone, but has 
been increasing, partly due to its better safety profile. Buprenorphine is a partial agonist, has weaker opioid effects 
and produces a lower level of physical dependence, but is less likely to result in overdose. It is often used in long-
term substitution treatment provided by office-based physicians. The fact that a broad range of substances, 
including heroin, is nowadays available for the treatment of opioid users, allows clinicians to engage a wider 
number of drug users in optimised pharmacological treatments. Detailed guidance for the psychosocially assisted 
pharmacological treatment of opioid dependence was published by the World Health Organization in 2009 (111). 
Quality and supervision: Treatment services must be well-organised, and of high-quality, including the level of 
training of staff, to achieve the best results. In particular, available international guidance on treatment regimens, 
dosage and supervision should be followed (111,129). Evidence indicates that flexible dosing structures should be 
encouraged, including a low starting dose and high maintenance dose, without restriction on dosage and duration 
of treatment (110,130). To optimise effectiveness of opioid substitution treatment, evidence further suggests that 
continuous treatment is more effective compared to short-term use of OST (108). Some forms of OST, such as 
methadone, will be less effective (i.e. have lower serum levels) if treatment for tuberculosis or HIV is taken at the 
same time; this should be monitored and the dose adjusted so that treatment is effective (131).  
Accessibility: The provision of OST via low-threshold services is an additional consideration. Low-threshold 
programmes are oriented towards harm reduction rather than abstinence, and are more flexible in terms of 
eligibility requirements and service provision, compared to high-threshold programmes. The combined use of other 
harm reduction services, which can enhance the effect of the treatment, is encouraged in these settings. During 
drug treatment, many infection-related services, such as provider- and client-initiated testing and counselling, 
vaccinations, infectious diseases treatment, or preventive equipment should be offered to people with a history of 
current or past injecting drug use. Mental healthcare (and additional general healthcare by general medical 
practitioners and, if available, internal specialists) should be combined with drug dependence treatment. The 
accessibility of such care is especially important for people who inject drugs who are in contact with low-threshold 
facilities. 
Dispensing: Opioid substitution medications can be dispensed in clinics, in specialised centres in the community or 
in pharmacies. In all settings, the direct supervision of the patient taking the medications can prevent diversion of 
drugs to the illicit market. However, take-home doses allow patients to follow family- or work-related obligations 
and lead a more ‘normal’ life. For all undergoing such treatment, regular medical examinations are an essential 
requirement (16,111).  
Flexibility regarding the start of treatment: Primary research results show positive effects of interim methadone 
maintenance treatment on risk behaviour (132). Readily available treatment in the form of interim methadone 
provision allows people who inject drugs to benefit from the protective effect of opioid substitution treatment on 
risk behaviour. 
Reaching difficult target groups: Long-term dependent heroin users who do not respond to standard treatments 
have been shown to benefit in programmes that provide supervised injectable heroin-assisted treatment (122). 
The delivery of HAT requires structurally adapted services to respect strict safety conditions and prevent any 
diversion to the illicit market. Clinics have to be open several sessions per day, every day of the year, in order to 
allow clients to inject their treatment under supervision as indicated in treatment guidelines (122). Although costs 
of this ‘second line’ treatment are higher than oral methadone treatment, this is compensated for by the significant 
savings to society – in particular the reduction in the cost of criminal procedures and imprisonment due to 
associated criminal behaviour (133). 
 
                                                                    
 
7 Pharmacological treatment with the opioid antagonist naltrexone, which blocks the effects of heroin and other opioids, plays 
only a minor role in Europe, as the treatment has been associated with high attrition rates.  
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Prison setting: Reviews of experimental and observational studies on OST in prison show that benefits of prison-
based maintenance treatment are similar to those in community settings (32,134-136). Making such treatment 
available in prisons presents an opportunity to reduce illicit opioid use and risk behaviours in prison. A good link 
between prison and community-based programmes is important to facilitate continuity of treatment (upon 
incarceration/after release), so that longer-term benefits can be achieved and high risks of harms, including death, 
in the period immediately after release, are prevented. 
Testing  
 
Considered judgement: Expert opinion is in favour of voluntary and confidential infectious disease testing for its 
potential risk reduction, and because a test-based diagnosis is a prerequisite for treatment provision. Due to the 
risk of infection associated with injecting drug use, it is likely to be cost-effective in all European settings to test 
people who inject drugs for HIV, hepatitis B, hepatitis C. TB testing is likely to be cost-effective in most countries. 
Tests for other infections should be considered in a standard offer for a medical examination (such as hepatitis A, 
D, syphilis and other liver and general blood tests). The frequency of medical examination and testing as well as 
the consideration of which tests to perform should be adapted to the individual clinical signs and symptoms and 
the local epidemiological situation. In the case of people who inject drugs, this risk is often very high and testing 
should, in that case, be offered up to once or twice yearly (16). 
A voluntary and confidential approach of routinely offered testing services is recommended. ‘Voluntary’ means that 
although testing is a standard of medical care, the individual is informed about the tests and their potential 
consequences and gives explicit consent to being tested. ‘Routinely offered’ means that care providers should 
recommended testing for infectious diseases as a standard component of medical care to people who inject drugs.  
However, estimates reported by countries in the EU/EEA suggest that only between 10% and 60% of people who 
inject drugs were tested for HIV during the prior twelve months (137), and this is likely to be much lower for other 
infections. Timely detection of blood-borne viruses and other diseases allow clients to seek healthcare to treat the 
infection, prevent complications, and reduce the risk of further transmitting the disease (138). Testing offers an 
important opportunity to counsel and educate people who inject drugs about preventing infection (if tested 
negative) and onwards transmission (if tested positive). Risk-reduction counselling conducted in relation to the 
testing situation can result in reductions in risk behaviours (139).  
Blood-borne infections 
Operational guidelines for healthcare providers to initiate testing of their patients who inject drugs for HIV, viral 
hepatitis and other infections, including bacterial skin infections, sexually transmitted infections, and respiratory 
infections were issued by the EMCDDA in 2010 and can be useful in guiding programmes when implementing 
testing for people who inject drugs (16). General guidance on HIV testing has been issued by ECDC (138). In sum, 
people who inject drugs should be offered testing that follows the quality standards of national guidelines. 
However, greater care may need to be taken to reach and counsel this more vulnerable and hard-to-reach 
population so that good access to testing can be achieved, the reason for testing is understood, and consent for 
testing is clearly voluntary. Providing point-of-care testing in outreach settings can increase the uptake of HIV, HBV 
and HCV tests (see text box below on the Finnish experience with point-of-care testing). Even if confirmatory 
testing of positive point-of-care tests takes as long as with regular tests, negative test results are immediately 
available, and preliminary positive test results combined with risk-reduction counselling may reduce risk behaviours. 
Testing should be linked to treatment of those infected, with referral through local treatment care pathways to 
specialist services for assessment and follow-up for those who are confirmed positive for HIV, chronic HCV and 
HBV or other infections that require treatment.  
Tuberculosis 
Screening for TB presents additional and important challenges which are crucial to address in the population of 
people who inject drugs. The control of TB relies heavily on detecting infectious cases and treating these for at 
least six months with a combination of antibiotics according to international recommendations (140-141). 
Patient delay in seeking care is common among people who inject drugs, which increases the risk for TB 
transmission and increases disease severity (142-143). Intensified case finding is important to reduce transmission 
and improve the treatment outcome and prognosis for the patient. TB screening can be performed to identify 
active or latent infection. From a public health perspective, identifying active TB is of key importance as it cuts 
immediate transmission. However, since people who inject drugs, and particularly those who are HIV seropositive, 
have an increased risk for progression to active disease, diagnosis of latent TB followed by preventive therapy is 
also important. Ideally, all people who inject drugs should be screened for active TB disease or latent TB infection.  
Recommended intervention 
Voluntary and confidential testing with informed consent for HIV, HCV (HBV for unvaccinated) and 
other infections including TB should be routinely offered and linked to referral to treatment. 
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TB screening is part of a comprehensive healthcare delivery process that requires access to microbiology services, 
treatment facilities, drugs and support for all diagnosed patients. TB screening/diagnosis includes medical history, 
chest x-ray, tuberculin skin testing (TST), and, if available, blood tests (interferon-gamma release assays, IGRA). 
The method used depends on national guidelines or, in their absence, on international guidelines for TB screening 
(131) (16) (144).  
In addition, the presence of signs and symptoms of TB in people who inject drugs should be identified through a 
clinical examination and, ideally, clients should complete a questionnaire on possible symptoms prior to testing. 
Any TB screening, especially in people who inject drugs with symptoms or signs of TB, should be followed by at 
least sputum smear microscopy, with full access to laboratory facilities with the capacity, technical experience and 
proficiency for culture of all suspected cases of TB. Upon suspicion of active TB, definite TB diagnosis should be 
based on microbiological culture confirmation, including susceptibility drug testing.  
It has been shown that people who inject drugs can be one of the groups with the lowest number needed to 
screen and treat prophylactically in order to prevent cases (145).  
Other infections affecting people who inject drugs 
Testing and treatment for sexually transmitted infections like chlamydia, gonorrhoea, and syphilis should be 
encouraged and be part of regular screening, especially among those with high-risk sexual behaviour and multiple 
sexual partners such as sex workers. Referrals, condoms and lubricants can be provided in all settings, even in 
settings where testing and treatment may not be possible to provide, such as outreach.  
Additionally, people who inject drugs are at high risk of developing acute bacterial skin infections (including MRSA), 
soft tissue infections, abscesses, and collapsing veins, with potentially life-threatening complications. Causes of 
infection are the injection itself (providing a route for skin bacteria into the body), poor hygiene, poor injecting 
techniques, and contaminated drugs (e.g. the 2010 anthrax outbreak in Scotland). It is important that minor 
injuries and bacterial infections are recognised (diagnosed) and treated in a timely manner. In cases of abscesses 
or other skin lesions, a bacteriological test from pus, tissue, or other material should be taken and sent to a 
laboratory for examination (15).  
  
Using point-of-care tests at low-threshold health service sites in 
Finland 
Since 1999, a point-of-care (PoC) rapid HIV testing programme has been implemented in low-threshold health 
service centres (LTHSC) serving people who inject drugs in Finland. In 2011, 10 out of 34 LTHSCs offered rapid 
HIV tests, evaluated and recommended by the National Institute for Health and Welfare (THL).  
THL supports the PoC testing programme by offering laboratory and counselling training, a quality assessment 
and monitoring programme and provides advice on the practical arrangements required for testing. Before 
introducing PoC rapid testing at a new LTHSC, all personnel required to work with rapid tests have to be 
trained at THL. The Institute organises HIV antibody quality assessment rounds in concert with external quality 
assessment services three times per year and performs confirmation testing for positive results. THL also gives 
day-to-day advice and monitors the testing programmes, collecting coverage and results data for programme 
surveillance and impact assessment.  
Clients are offered free, anonymous, and rapid HIV tests in all LTHSCs, without the need for an appointment. 
The test is performed in a separate testing area that ensures privacy. Pre-test counselling includes a discussion 
of risk behaviour, safe sex practices, and the window period for HIV antibodies. The test is performed from 
blood collected by a finger prick, and the result is available within 15 minutes. Negative test results are given 
immediately after the test, positive results are further confirmed from separately drawn venous blood. The 
confirmatory result is ready after one week. Positive cases are referred to hospital care.  
Between 1999 and 2010, more than 8000 samples from people using drugs were tested in LTHSCs, resulting in 
a total of 47 confirmed HIV-positive cases. The overall acceptance of the rapid test format among healthcare 
personnel and LTHSC clients has been positive. Most of the clients prefer PoC rapid testing to conventional 
testing. 
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Infectious disease treatment 
 
Considered judgment: Recent studies have demonstrated clear benefits of antiviral treatment against HIV, HBV 
and HCV among people using drugs. Recent international guidelines do not restrict antiviral treatment to people 
who are drug-free, as long as there are no other clinical contraindications. There is strong evidence for the 
individual and population-level benefits of TB treatment.  
Practical considerations: Testing should be closely linked to treatment, with clear referral patterns in place to 
provide care continuity to cases tested positive and medical monitoring of disease progression if treatment is not 
yet indicated. The high prevalence of co-infections among people who inject drugs needs to be considered. 
Referral and ensuring continuity of care for disease treatment is especially crucial when planning for release from 
prison. Drug interactions need to be carefully considered, especially in co-infected individuals. 
Blood-borne infections 
Provision of antiretroviral treatment (ART) is an essential part of care for people who inject drugs that are tested 
positive for HIV. For those tested positive for hepatitis B or hepatitis C infection, the provision of antirviral 
treatment is often clinically indicated and should be provided in accordance with national guidelines (1,53,146-148). 
All individuals with HIV or chronic hepatitis B or C require regular medical review even if they are not receiving 
antiviral treatment.  
There is evidence that active drug injectors can successfully undergo treatment for HIV and benefit from it. There 
is equally strong evidence that there is no higher drug resistance in user populations than in other HIV-positive 
individuals who receive antiretroviral treatment (149). Research has also shown that people who inject drugs can 
achieve hepatitis C treatment outcomes comparable to those found in the non-injecting general population, if the 
treatment was accompanied with appropriate support (150). There is evidence that treatment for hepatitis C can 
be delivered in the framework of opioid substitution treatment programmes, and that both clients and staff support 
this ‘one-stop shop’ model of service provision (151-153).  
Multiple studies have confirmed that those who are HIV positive or HIV and HCV co-infected and who receive OST 
are more likely to adhere to the treatment regimen of their infection(s), but there is no evidence on how this 
impacts viral load. (Further details regarding the impact of OST on adherence to ART can be found in the WHO 
Clinical Protocol for the European Region (1)).  
There is also evidence from modelling studies that anti(retro)viral treatment for HIV and hepatitis C may influence 
the prevention of transmission of infectious disease: when adhering to treatment, the viral load can be reduced, 
thereby reducing the risk of onwards transmission, in addition to preventing complications of the infection for the 
individual HIV- or hepatitis C-positive person who inject drugs (154).  
Post-exposure prophylaxis of HIV infection and Hepatitis B can be considered in accordance with international and 
national recommendations. 
Tuberculosis  
All patients diagnosed with active TB should be provided with the adequate treatment. Treatment should follow 
national guidelines or, in their absence, the international guidelines (140-141), which also provide specific guidance 
for special clinical situations such as co-morbidities like HIV infection. Response to treatment needs to be 
monitored clinically and bacteriologically. When a patient is found positive for active TB, contact tracing of index TB 
cases needs to be ensured.  
In individuals with known HIV infection living in settings with a clear risk of recurrent TB exposure and in whom 
active TB is excluded, prophylactic treatment should be considered after an individual risk assessment. Also, where 
antiretroviral treatment is available, the achievement and maintenance of adequate CD4 counts in HIV-infected 
individuals will keep these individuals at a lower risk to develop TB after exposure. This should be taken into 
consideration in the individual risk assessment.  
The use of prophylactic treatment in HIV-infected individuals should follow the ‘WHO interim policy on collaborative 
TB/HIV activities’ (155) and the ‘Policy guidelines for collaborative TB and HIV services for injecting and other drug 
users. An integrated approach’ (156).  
According to the international standards for TB care, the strategy for patient adherence should include measures to 
both assess and promote adherence, and provisions should be made to address poor adherence. Therefore, 
directly observed treatment (DOT) is recommended to ensure multidisciplinary approaches in order to support the 
Recommended intervention 
Antiviral treatment based on clinical indications for those who are HIV, HBV or HCV infected. Anti-
tuberculosis treatment for active TB cases. TB prophylactic therapy should be considered for 
latent TB cases. Treatment for other infectious diseases should be offered as clinically indicated. 
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patients and enhance treatment adherence. Incentive programmes to promote adherence to follow the DOT may 
be useful (157). 
Other infections affecting people who inject drugs 
If identified, sexually transmitted infections should be promptly treated according to national guidelines. Long-term 
injection often leads to chronic, non-healing wounds among people who inject drugs. Wound management 
procedures can be very effective if the client-staff relationship is stable and based on trust and adherence to the 
treatment. Wound care services should be offered along with needle and syringe services, as well as drug 
treatment, if possible.  
Health promotion 
 
Considered judgment: Health promotion is supported by expert opinion as a fundamental companion component 
for the delivery of all six interventions. It provides support for the implementation and social marketing of other 
direct interventions. Contents should be guided by user needs. 
Health promotion is the ‘process of enabling people to increase control over their health and its determinants and 
thereby improve their health’ (WHO 1986). Health promotion includes not only information giving and support, but 
also risk-reduction counselling. Health promotion alone is not effective in reducing the risk of HIV among people 
who inject drugs, but combined with other prevention measures such as needle and syringe provision and drug 
treatment, health promotion can be effective (53,158). Health promotion messages should be gender and culturally 
sensitive, provided in different languages, and adapted to use terminology that is familiar to users and that they 
will easily understand.  
 
Apart from written materials, there should be visual and interactive educational tools. Persons delivering health 
promotion activities should be specifically trained on how to provide health education. It is important to keep in 
mind that health promotion may need to be tailored to special personal conditions such as mental illness. This 
might influence the success of health promotion efforts.  
The purpose of providing health promotion messages to people who inject drugs is to increase understanding 
about infectious diseases, infection transmission, and infection prevention, with the aim of reducing the risk of 
contracting and transmitting infectious diseases through the injection of drugs by promoting safer injecting 
behaviour, transition to non-injecting drug use, or cessation of drug use. Health promotion messages should be 
tailored to the needs of the user and provided at every possible opportunity: whether on a street corner when 
providing outreach services or in a drug treatment centre or a needle and syringe programme. Every contact with a 
person who is currently injecting drugs is a chance for a service provider to assess health promotion needs and to 
provide counselling and health promotion messages. Clients are often the best judge of their own needs for health 
Health promotion for safer injecting behaviour 
• Use a new sterile needle and syringe and clean equipment for each injection: ‘one needle – one syringe 
– one time’. Never share or borrow needles, syringes or other equipment.  
• Be aware of, and prepared for, situations where it may be difficult to prevent infections. For example, if 
there is social pressure to share utensils or if the situation is somewhat chaotic when preparing an 
injection. Enact strategies to reduce the likelihood of unintentional sharing of injecting equipment (such 
as using colour-coded or labelled syringes).  
• Encourage peers who do not inject not to start injecting. Encourage peers who do inject to use safe 
injection practices.  
• Wash hands before and after injecting; clean the skin before injecting with alcohol or another 
disinfectant; use a filter; avoid the use of dangerous injection sites such as the neck and groin; avoid 
injecting under the skin or directly into a muscle; and clean all materials, including the table surface, 
with a disinfectant following injection. 
• Rather than injecting, use non-injecting routes such as smoking or orally ingesting the drug. Foil or 
gelatine capsules can be used for these purposes.  
• Prevent overdose by using smaller amounts of drugs (especially after periods of abstinence or less 
intense drug use), by not using drugs while alone, and by recognising signs of overdose in injecting 
partners and calling for help immediately upon their recognition. Take care when using drugs from new 
or unknown sources, and avoid mixing drugs such as alcohol, benzodiazapines and opioids. Utilise 
supervised health facilities for hygienic injecting, if such services are available. 
Recommended intervention 
Health promotion focused on safer injecting behaviour; sexual health including condom use; and 
disease prevention, testing and treatment. 
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promotion information and, if trust is built up with the service provider, some clients will seek health information 
based on the needs that they themselves have identified. 
Safer injecting behaviour 
Key health promotion messages to promote safer injecting behaviour are listed in the box above. These should be 
adapted to the local context and the needs of specific users and individual lifestyles.  
While the main focus of this guidance is on the prevention of infections among people who inject drugs, the main 
cause of mortality in opioid-using populations in many settings is still drug overdose (159), and health promotion 
related to overdose prevention is a key activity that those who work or come into contact with people who inject 
drugs should be engaged in. It is particularly important to reach people who are currently participating in formal 
drug treatment, undergoing drug detoxification, and those who inject drugs and are to be released from prison, 
and let them know that if drug use is resumed or intensified, they are at high risk for drug overdose due to 
reduced drug tolerance. Key overdose prevention messages directed at people who inject drugs can also promote 
the use of smaller amounts of drugs or encourage the recipients not to use drugs while alone (31). Training 
activities can be provided to instruct drug users how to recognise the signs of overdose in injecting partners and 
what to do in an emergency, e.g. putting victims in the recovery position and calling for an ambulance. Peer-
delivered naloxone is used in some countries and positive results were reported (160). Additional possibilities to 
reduce the likelihood of harm associated with drug overdose are to encourage people who inject drugs to utilise 
supervised injecting facilities, if such services are available. Due to direct supervision by staff, immediate help is 
available in case of overdose. A recent study has documented an association between the existence of such 
facilities and the reduction in overdose deaths at population level (161). Finally, the vast majority of those who 
begin injecting do so in the company of peers with established injecting drug use. Key messages for health 
promotion, for example how to avoid being initiated into injecting drug use or how to use safe injection practices 
are most effectively delivered by peers.  
Sexually transmitted infections and condom use 
Data from EU/EEA countries on condom use among people who inject drugs range from less than 5% to nearly 
60%, far lower than is necessary to prevent the spread of sexually transmitted infections, including viral hepatitis 
and HIV (137). Thus, it is particularly important that health promotion activities target the sexual transmission of 
infections among people who inject drugs. Condoms and lubricants should be provided along with information on 
their consistent use. Additional information should be given on screening and treatment for sexually transmitted 
infections, since there is evidence for the sexual transmission of infections, including HIV and hepatitis B, from 
people who inject drugs to and from their sexual partners (162-163). Drug use can also be associated with the 
exchange of sex for money or drugs, which puts users at a much higher risk of contracting or transmitting sexually 
transmitted infections if condoms are not used consistently and correctly. 
Disease prevention, testing and treatment 
Health promotion should include information which clarifies routes of transmission for diseases that are common 
among people who inject drugs. Information on infections like HIV, HCV and HBV should be provided, so that 
people understand that they can transmit the virus even if they show no symptoms. In the case of TB, there is 
often confusion regarding infection and disease, and which stages are infectious (142) (143) (164). Studies have 
suggested that HIV prevention information can be confused with TB prevention, such as the incorrect notion that 
TB can be prevented by condom use or bleaching needles, which may explain the longer patient delay in some 
settings (142). 
Comprehensive, easily accessible information material as well as an active dialogue about TB and blood-borne 
viruses is essential. Equally important are efforts to correct misconceptions about disease while at the same time 
counteracting the stigmatisation of disease. Key health promotion messages should also focus on supporting the 
adherence to treatment so that the patient can be cured (TB, HBV and, if successful, HCV), thus reducing the risk 
of developing resistance towards the drugs and transmitting the infection to others.  
A final important issue for many people who inject drugs is social support and social care. There is evidence that, 
for example, supervised housing is associated with a decreased risk of infection for people living with HIV (165). It 
is likely that many structural factors related to housing and economic well-being have a major impact on the 
quality of life and infection risk for many people who inject drugs. The provision of supportive services that address 
the extended needs of people who inject drugs such as housing, food, and low-threshold employment 
opportunities are likely to have a positive impact on health-related outcomes.  
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Targeted delivery of services 
 
Considered judgment: Evidence and expert opinion supports a targeted delivery of services according to user 
needs and local conditions. 
Modes of service delivery: considerations for attracting users to services 
As defined by the core principles of service delivery, it is essential to carefully consider how services for people who 
use drugs are organised and delivered in order to maximise their acceptability to clients and, thereby, service 
access and uptake. The effectiveness of service programmes depends on their ability to attract, motivate, and 
retain clients. Therefore, the planning of the services should aim at creating as low a threshold as possible for 
people who inject drugs, so they can easily attend and use the services provided. 
Services must be delivered in locations that potential service users can recognise, access and feel comfortable 
entering. Additionally, services should be provided in a discrete environment and manner, where confidentiality can 
be ensured, and where clients do not feel threatened by judgmental attitudes of staff, by harassment, or have to 
fear arrest by law enforcement authorities. Sometimes offering the most basic social services, such as food, 
showers, and clothing, is a way to attract the most socially excluded and at-risk people who inject drugs to services. 
Service access must be carefully planned based on the local context. Easy and timely access to services is 
particularly crucial in the provision of needles, syringes, and injecting equipment. Reducing the spread of HIV, 
hepatitis B, and hepatitis C is impossible without a constant supply of clean injection equipment.  
Services for people who inject drugs will vary by country, region, available resources, and sub-population. This is 
mostly because characteristics of people who inject drugs will differ between and within countries, depending on 
the type of drugs used, age, gender, ethnic background, and income level. It is, thus, very important to involve the 
target population when designing and choosing delivery modes for service programmes in order to best address 
the local needs and context. If programmes are tailored to address the clients’ needs and service preferences, 
there is a better chance of increased uptake of services.  
 
Minors’ access to needle and syringe programmes in Hungary 
When the country’s first comprehensive national guidelines for NSPs were developed in Hungary in 2010*, the 
need for a national consensus on the access of minors (legal age in Hungary: 18) to such services arose. The 
project’s principles of anonymity, confidentiality and easy and unrestricted access to services, which are 
considered among the main advantages of low-threshold services for drug users, made it impossible to restrict 
NSP service access. At the same time, local regulations stipulated to report ‘at-risk’ children to child protection 
authorities.  
The contradictory legal frameworks were the starting point for a national discussion process, bringing together 
experts from child welfare, representatives of all Hungarian NSPs and other stakeholders in a national meeting. 
Following presentations of international as well as local practice, and discussions about topics such as the need 
of minors for multiple services, such as in-depth pre-counselling and individual case assessment, the way for a 
consensus was paved. It was agreed that besides the upcoming general guidelines for the national level, each 
NSP should reconsider its own internal regulation, while at the same time child protection services should build 
partnerships with the with relevant drugs services, so that they could refer minors to drug counselling and 
treatment services. Regarding the contradiction between child protection legislation and low-threshold services, 
the ombudsman was asked for a resolution, which is reflected in the guidelines. 
The final national guidelines for NSPs, published in July 2011 by the National Institute for Family and Social 
Policy, state that minors should not be excluded from NSPs, as anonymity is of high priority in such 
programmes. But the guidelines also made clear that minors should be encouraged to inform their parents. 
Where appropriate, it is recommended that the local child welfare service provider as one of the main local 
partners of NSPs is contacted. Based on the assessment of each individual case, co-operation and exchange of 
information between both organisations is considered beneficial for under-age clients of NSPs.  
* The guidelines were formulated in the framework of an EU-funded priority project: ‘Modernization of social services, reinforcement of central 
and local strategic planning capacities, supporting social policy decisions’ of the Social Renewal Operational Programme. 
Recommended intervention 
Services should be combined and organised and delivered according to user needs and local 
conditions; this includes the provision of services through outreach and fixed site settings, 
offering drug treatment, harm reduction, counselling and testing, and referrals to general primary 
health and specialist medical services. 
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Types of service delivery 
There are a variety of modes of service delivery, each of which can function in combination with other services or 
in isolation. Many countries have found that integrating services into a ‘one-stop shop’ model of services with a low 
threshold for attendance is a more cost-effective and efficient way of delivering services, and that service 
integration is appreciated by clients (120,166-167). An example of a highly integrated, fixed-site service setting 
would be a site that provides needles, syringes and injection equipment, testing and possibly medical care (e.g. 
treatment for HIV, hepatitis B and C), general health information about hygiene and overdose prevention, referrals 
to drug treatment, and general health and social services. (See text box with examples of service integration on 
page 29.) 
If it is not possible to integrate services due to health system organisation, funding, or client preferences, there is 
still great value in delivering individual services to address client needs. Many programmes begin with one mode of 
service delivery, and then add additional services as time goes on. Service delivery modes should be adapted to 
maximise effectiveness with regard to local needs. These service delivery modes have a variety of names, 
depending on the setting, but the general characteristics usually fall into the following categories: 
Fixed sites: Services can be, and often are delivered through facilities at a fixed site which specifically target 
people who use drugs and aim at maintaining a low threshold for attendance (i.e. very few restrictions of use and 
a client perspective to service provision), to make access as easy as possible for users. Fixed-site services can be 
needle and syringe programme sites or opioid substitution or other drug treatment sites, which might also provide 
additional services for people who inject drugs, such as testing for HIV, hepatitis or TB, health education, or 
referral for treatment. Fixed site services may serve as a ‘drop-in’ centre or a place to be for people who inject 
drugs. The service site, which provides health and prevention services, can also be a place to rest, eat, read 
newspapers, use the internet and talk to staff and peers in a relaxed and accepting atmosphere. Fixed-site services 
provide an important place for peer education and often serve as a base from where professionals and peer 
workers conduct outreach activities. Needle and syringe programme sites often serve as a gateway to attract 
clients. Initially, many clients visit service sites for the social connections, syringes or drug preparation equipment 
provided there, but then come into contact with a range of other services and health education messages.  
In more than 50 European cities8, spaces where drugs can be consumed under the direct supervision of health 
staff have been integrated into specialised fixed-site facilities. Such supervised injecting facilities are professionally 
run healthcare facilities where hygienic and safer use is promoted to reduce the morbidity and mortality associated 
with drug injecting (5). The facilities provide opportunities for health education and disease prevention and for 
immediate intervention by professionals in cases of overdose. A main objective is to reach out and stay in contact 
with people who are not able or willing to quit injecting drug use, to reduce health risks, and to provide access to 
other services, in particular medical care and drug treatment. Research has shown that supervised injecting 
facilities reach specific hard-to-reach target groups, and that service users report substantial reductions in risk 
behaviour as well as improved health.  
Regardless of their type, fixed-site services should be located in an area in which sizeable clusters of people who 
use drugs live or spend time, or, alternatively, where large numbers of potential clients can easily obtain access to 
the service site. Fixed-site services are typically run by specialised staff; these should be well-trained to provide 
services and education in a client-centred and non-judgmental way. Advantages of fixed sites are that multiple 
services can be delivered in one location, and the services delivered can be tailored to the needs of the local 
population. For example, clients can select the types of needles, syringes and injection equipment they prefer, 
thereby minimising waste due to pre-packed kits that often include items that clients do not want or need. 
Disadvantages of fixed sites include that they can be expensive to run, which may limit opening hours and, in turn, 
access to services. Fixed sites can also be difficult to access for users outside of the immediate geographical area 
of the site. Therefore, attention must be paid to mapping the needs for services and matching those needs to sites 
that are easily accessible and offer convenient opening hours to as many people who inject drugs as possible. 
People who inject drugs and live in hard-to-reach areas may require mobile outreach services (see below).  
Sometimes, fixed sites face negative reactions in the neighbourhood if they are viewed as attracting a problematic 
population, thus intensive communication within the community is needed to overcome these concerns. Fixed sites 
can also be viewed by clients as affiliated with undesired service providers, for example, government programmes, 
which in some settings can limit uptake. Services providing outpatient drug dependence treatment typically 
combine further health and social service offers relevant for the target group of injectors, including infectious 
disease prevention measures like counselling and testing, vaccinations, and referral to specialist care.  
Pharmacy sites: In the majority of EU/EEA countries syringes are sold legally. In some countries, pharmacies are 
the main supplier of needles and syringes. Pharmacies can act as sales or distribution points for needles, syringes 
and injecting equipment, and can be service points for the collection of used needles and syringes. Testing or 
vaccination services could also be supplied by pharmacies to people who inject drugs. One example, from Scotland, 
 
                                                                    
 
8 These cities are located in Germany, Luxembourg, the Netherlands, Norway, Spain and Switzerland. 
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uses an electronic system to track individual clients through the use of an anonymous card. With the card, clients 
can obtain free sterile needles and syringes from pharmacies. The system can also track those in need of referral 
to testing or vaccination services and provides information on the number of needles and syringes dispensed per 
client for health service planning. Furthermore, the community pharmacy can be an active partner in opiate 
substitution treatment, dispensing medication to registered patients, maintaining regular contact, reminding clients 
of medical appointments, or managing additional medication. Referral and follow-up to vaccination services can 
also be managed through this system. The main benefit of pharmacy services is that they can be more accessible 
to more people who inject drugs, both in big cities and in small towns, thanks to an existing infrastructure, which 
also reduces costs. However, most pharmacies focus on serving the general public and many are privately run, 
sometimes decreasing the feasibility and acceptability of providing services to people who inject drugs, who can be 
viewed as undesirable or non-paying clients. Client confidentiality and the possibility for more extensive health 
promotion can be an issue if the pharmacy has no private consultation area or lacks personnel. Finally, needles and 
syringes provided through pharmacies are often given in pre-packaged bundles, effectively limiting individual 
choice. While pharmacy-based distribution of services to people who inject drugs is a very effective method of 
service provision, pharmacies cannot cover all user needs.  
Outreach services: Because many sub-groups of people who inject drugs are difficult to access through general 
health services, outreach services often provide an effective way of delivering services, for example the provision 
of needle, syringe and injecting equipment. Outreach services can also deliver condoms, opiate substitution 
treatment, and health promotion messages (158). ‘Outreach’ is a generic term used to cover several types of 
service delivery and can include mobile units or vans, street outreach by community health workers, and regular 
satellite services based at other agencies. Often outreach services are able to reach people who are not in contact 
with other health services and thus play an important role in identifying their needs for referral to fixed-site or 
general health services, such as HIV, hepatitis or TB testing or treatment, or drug treatment. (For more 
information on outreach see (158,168).) Outreach can include home visits, and outreach workers can accompany 
clients to other services. One benefit of outreach services is that, due to their mobility, they are often highly 
accessible to different populations of people who inject drugs because they can easily move into new areas with 
high concentrations of people who inject drugs. Mobile units can provide services, including the dispensing of 
opiate substitution medications in settings where fewer people who inject drugs are concentrated or where fixed 
sites are not possible due to community or law enforcement opposition. Sometimes cost considerations limit the 
extent to which mobile outreach is possible, and the hours of operation have to be curtailed. One review found 
that outreach services were seen by people who inject drugs as not providing a full range of services (169).  
Peer-delivered services are a type of outreach service (although services can also be delivered from fixed sites) 
delivered by current or former drug injectors in order to refer other people who inject drugs to service centres. If 
no formal services are wanted, peer-delivered services distribute needles, syringes and equipment (this is 
sometimes referred to as ‘secondary needle distribution’). Peer-delivered services can provide much easier access 
to the most at-risk populations, including new or young injectors. Peers handle equipment distribution, referrals to 
drug treatment (or other treatment and testing services), and health promotion messages in the language of the 
local drug use scene. Messages delivered by peers can thus have a greater impact (and lead to better intervention 
uptake) than those delivered by health workers – a big advantage, especially when taking into consideration that 
persons obtaining needles and syringes through secondary distribution services often show extreme high-risk 
behaviour. If peer-delivered services are used, training, supervision and support are particularly important, as well 
as thorough consideration of the ethical implications of employing former or current injectors to conduct outreach 
services to people who inject drugs. For more resources on this see (158) and (168,170).  
Vending machines: Vending machines are used in some settings as a complementary method of distribution of 
needles, syringes and equipment, usually in the form of pre-filled packets. They are coin-operated and provide 
written drug treatment referral, safe injection information, and other health promotion messages along with the 
products dispensed. This mode of service delivery is always available to potential users and is highly anonymous, 
often attracting new or younger injectors. However, this type of service requires money or tokens to operate the 
machine, and a plan must be in place to ensure regular refilling and maintenance of the machines. Community 
concerns about the placement of vending machines are not uncommon, as are fears that minors can access them. 
It should also be obvious that syringe vending machines cannot provide a direct link to the service provider, which 
makes referrals to testing and treatment and face-to-face health promotion impossible. However, they can be a 
first step, offering the possibility of contact, generating name recognition as well as a certain level of confidence in 
the organisation running the syringe vending machine (171).  
General health services: Hospital or primary care settings are another important source of service delivery and 
referrals to specialised services for people who inject drugs. Confidential testing, diagnosis and treatment for HIV, 
viral hepatitis, TB, bacterial skin infections and other diseases common among people who inject drugs are 
typically conducted in general health service facilities, and maintaining strong referral links between these services 
and fixed sites or mobile settings which serve people who inject drugs is important. General health services can 
also provide needles, syringes and other injection equipment, supervise hygienic injecting, assist during drug 
detoxification, provide condoms, and promote health in general. TB and HIV clinics are often organised by general 
 
 
 
 
ECDC AND EMCDDA GUIDANCE Prevention and control of infectious diseases among people who inject drugs 
 
 
 
29 
 
 
 
health services. Given the high proportion of people who inject drugs among clients, it is crucial that staff at 
general health service facilities are properly trained on pertinent health promotion messages and can either refer 
people to drug treatment and needle and syringe services, or know where referrals can be made. Ideally, all 
people who inject drugs would seek and receive high-quality mainstream health services. However, there is 
evidence from some settings that people who inject drugs only rarely visit general health service facilities, and 
alternative ways of reaching them are necessary. In the Netherlands, specialised services for people who inject 
drugs and other risk groups are offered alongside general health services. There are also examples of integrating 
drug and medical services (a ‘one-stop shop’ model) into one programme, which facilitates treatment adherence 
and completion (153,172-174). Examples are directly observed TB treatment and HCV antiviral treatment, both 
combined with methadone maintenance treatment. General health services are easily accessible to clients, 
particularly their emergency departments, which are always open. Care must be taken to sensitise both health and 
non-health staff in these more general health settings to the issues of people who inject drugs and to delivering 
non-judgmental and confidential care to them. In some countries, some general health services provide 
anonymous testing. 
Prison settings: Finally, it is important to mention that many countries provide services to IDU populations in 
prison systems, and that prison settings are key to achieving a high and effective coverage of services for the 
prevention of infection among people who inject drugs. Correctional facilities are an important setting for injection-
related infection prevention and control. The main reasons are: (a) the high prevalence of HIV, HCV and TB in 
prisons; (b) the fact that many people who inject drugs eventually get sentenced to a prison term; and (c) 
evidence that drugs continue to be used and also injected in prison – despite the strict prohibition of drugs (5). In 
some countries, the prison systems offer drug treatment, disease testing and treatment, vaccinations, health 
education, and even needle and syringe programmes. Following the principle of ‘equivalence of service provision’ 
between community and prison, there is a movement in many countries to provide the same services for people 
who inject drugs in prison settings as for people who inject drugs in the community.  
The described modes of service delivery can be effective in targeting people who inject drugs. Emerging new 
methods for the delivery of health promotion information, such as mobile phone- and internet-based messaging 
show promise in improving treatment adherence. While services will at times only employ one mode of delivery, it 
is more likely that effective programmes will provide several services in one location or several modes of service 
delivery to reach the diverse needs of users. In order to better link programme services, it is essential that multiple 
services be co-located at the same place so that users can access them conveniently (see text box below on 
service integration). Additionally, outreach workers, case managers, and healthcare providers should receive 
further training in the treatment and/or case management of co-morbid conditions; areas of training should include 
drug treatment, the treatment of TB, viral hepatitis, and HIV. Specialist providers should also be involved in the 
care of such patients. In addition to these co-morbidities, there are often mental health diagnoses which 
necessitate good case management. Increased awareness and training can lead to enhanced monitoring of drug-
drug interactions and adverse side effects, as well as maximise treatment outcomes and improve a client’s quality 
of life.  
 
  
Service integration 
There are many successful examples of linking services for people who inject drugs in order to increase access 
to services, harmonise treatment, and optimise the distribution of prevention messages, thereby increasing the 
likelihood of treatment adherence and success. Co-location of service delivery sites for TB, viral hepatitis, HIV 
and opioid substitution treatment and/or needle and syringe programmes is an option that is in practice or 
under development in some countries. Not only is the physical proximity of services an advantage, but 
communication and sharing of expertise across different healthcare programmes also benefit from this (202-
204) (143) (142).    
A recent pilot programme in Estonia has shown that the uptake of TB screening services can be increased by 
offering TB screening at opiate substitution treatment facilities and more active referrals to TB services 
(reminders, incentives, transportation) (172). When planning service facilities, provisions for the co-delivery of 
services should be made. For example, HIV-seropositive persons who are not infected with TB should be kept 
apart from patients with active TB, due to the increased risk of TB infection for HIV-positive people.  
Services could build off of existing drug rehabilitation programmes, syringe distribution programmes, or service 
providers for TB directly observed therapy (DOT), depending on what is considered best for particular setting. 
Mobile outreach healthcare programmes may be useful to reach certain populations of people who inject drugs, 
in particular through mobile radiographic screening units. Such units have been shown to have a positive effect 
on the reduction of TB among people who inject drugs in Rotterdam, Netherlands (205). 
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Table 1: Modes of service delivery targeting people who inject drugs and their strengths and 
limitations 
Model type Types of services that could be 
provided to people who inject 
drugs 
Strengths  Limitations 
Fixed site 
dedicated low-
threshold 
services 
• Injection equipment 
provision/disposal 
• Counselling  
• Drug dependence treatment 
including opioid substitution 
treatment 
• Testing for HIV, hepatitis B, C 
and TB 
• Vaccination 
• Place to be 
• Food, shower, clothing 
• Peer education 
• Health promotion 
• Safer use education, incl. 
overdose prevention and 
management 
• Supervised facilities for hygienic 
injecting  
• Safer sex health promotion and 
condom distribution 
• Supervised antiviral treatment 
(or directly observed therapy for 
TB) 
+ Potential for creating sense of 
belonging for clients 
+ Potential to provide multiple 
services in one location 
+ Can achieve favourable 
cost/client coverage ratio 
+ Can offer service provision 
tailored to clients’ needs 
+ Usually run by specialist staff 
+ No opposition by other clients 
+ If well organised, access is 
easy 
+ Provides a base for other 
services like outreach services 
- Fixed site might limit access of 
those who do not live in the 
vicinity 
- Can be expensive to run 
- Can have limited opening hours 
- Potential for harassment by 
police or other law-enforcement 
agents, particularly if cooperation 
contacts are not 
established/managed 
- Personnel security risk may be 
increased if not well managed 
- Potentially less access to short-
term or young injectors 
- Fixed site might be more difficult 
to establish due to opposition in 
the neighbourhood  
 
Pharmacy 
services 
• Injection equipment 
provision/disposal 
• Dressings 
• Health promotion 
• Confidential testing 
• Information and referrals 
(infectious disease testing and 
treatment, vaccination and drugs 
services) 
• Provision of (rapid) tests for 
HIV/hepatitis C 
+ Accessible/good geographical 
availability 
+ Wide opening hours  
+ Can be cost-effective  
+ May be considered more 
anonymous 
+ Access to medical 
advice/medially trained staff  
+ Uses existing infrastructure  
 
- Payment may be required 
- Limited opportunity for health 
promotion and referral in busy 
pharmacies 
- Provision of pre-packed bundles 
reduces options for user 
preference 
- Reluctance of pharmacists to sell 
syringes to people who use drugs 
- Opposition of other clients 
Outreach 
services 
(including peer-
delivered 
services) 
• Injection equipment 
provision/disposal 
• Health promotion 
• Information about appropriate 
specialists, clinics and medical 
services 
• Referrals to infectious disease 
testing and treatment, 
vaccination, and drugs services 
• Home visits, prison visits 
• Accompanied referrals to other 
services 
• Provision of rapid tests for 
HIV/hepatitis C 
• Counselling 
+ Responsive and easy to adapt 
to user needs 
+ Flexible regarding changing 
locations where people who 
inject drugs can be reached 
+  ‘Early warning’ potential: 
Professionals learn what is 
happening among users 
+ Accessible, especially to hard-
to-reach and high risk users 
(young/new users, migrant 
users) 
+ Peer-delivered services can 
increase service efficacy 
 
- Not all services can be provided 
- Cost and maintenance (mobile 
units) 
- Limited hours  
- More expensive staff time (due 
to time spent driving, etc.) 
- Some mobile units could make 
users feel too 
observed/uncomfortable  
- Peer-delivered services must be 
well supervised and require 
training 
 
Vending 
machines 
• Injection equipment 
provision/disposal 
• Referrals to infectious disease 
testing and treatment, 
vaccination, and drugs services 
• Health promotion (in written 
form) 
+ Always accessible (especially 
to young/new users) 
+ Cost-effective 
+ Anonymous  
 
- Not all services can be provided 
- No personal contact possible 
- Potential for community concern 
about machine placement 
- Payment or tokens required 
- Maintenance and re-stocking 
must be ensured 
 
 
 
 
ECDC AND EMCDDA GUIDANCE Prevention and control of infectious diseases among people who inject drugs 
 
 
 
31 
 
 
 
Model type Types of services that could be 
provided to people who inject 
drugs 
Strengths  Limitations 
General health 
services 
• Confidential testing for HIV, 
hepatitis B, C and TB 
• Treatment of HIV, hepatitis B, C 
and TB 
• Care of skin infections/dressings 
• Vaccination 
• Health promotion  
• Injection equipment 
provision/disposal 
• Assistance with drug 
detoxification 
• Opioid substitution treatment 
 
+ Accessible 
+ Access to trained staff 
+ Access to more/advanced 
testing and treatment services 
+ Access to mainstream health 
services (services used by the 
rest of the community)  
 
 
- Might not be tailored to user 
needs 
- Some health staff may be 
reluctant to provide care to 
people who use drugs 
- Opposition of other clients 
- Clients might be reluctant to use 
site if e.g. perceived as too 
closely affiliated with government 
services 
- Clients may not trust 
confidentiality  
- Anonymity may be difficult to 
ensure for all services 
- Limited/no access to individuals 
without health insurance  
- Stigma 
Services in 
prison settings 
• All services available to drug 
users in the community 
 
Examples include: 
• Confidential testing for HIV, 
hepatitis B, C and TB 
• Treatment of HIV, hepatitis B, C 
and TB 
• Vaccination 
• Health promotion  
• Injection equipment 
provision/disposal 
• Assistance with drug 
detoxification 
• Counselling 
• Drug dependence treatment, 
incl. OST 
+ High risk groups can be 
reached 
+ Interventions are cost-effective 
+ Risk of post-release 
mortality/morbidity can be 
reduced 
+ Community-based agencies 
can deliver services 
+ Easier possibilities to provide 
disease treatment  
+ Time for health promotion 
 
- Prison health budget may be 
insufficient 
- Investment in training of prison 
health staff and officers needed 
- Confidential service provision 
may be difficult to ensure 
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Knowing and understanding the national 
situation 
The epidemiology of both drug use and infections among users is subject to rapid changes due to different illicit 
drugs, changing drug cultures and population movement. The dynamics of these changes are complex, multi-
factorial and dependent on social and economic situations, prevention activities, and other societal factors (175).  
In order to ensure that national or sub-national strategies best serve the population of people who inject drugs, as 
well as prevent and control infectious disease, there must be sufficient surveillance of drug use and infections 
among people who inject drugs. Similarly, measures taken should be continuously monitored and evaluated in 
terms of response, impact, relevance, and scale of coverage. Such monitoring is necessary not only to ensure that 
prevention remains relevant, but also to maintain effectiveness both in terms of health impact and cost.  
To ensure that prevention resources are well spent, infectious disease prevention efforts should be targeted to 
populations of people who inject drugs and where the risk of transmissions of infections is greatest. Investment in 
adequate surveillance systems for both drug use and infectious disease is necessary and likely cost-effective. 
Failure to implement such systems may not only hide a growing problem, leading to high health and social costs, 
but also result in ineffective use of resources. 
Monitoring problem drug use and responses 
Surveillance of problem drug use is a necessary component of any national effort to prevent harm caused by drugs. 
A review of this activity is beyond the scope of this guidance, but the EMCDDA has issued a set of key indicator 
protocols and toolkits for monitoring drug use and problem drug use (including injecting drug use) and their 
consequences (4).  
Estimating the size of the populations of people who inject drugs is a key component of surveillance; these 
estimates not only quantify the magnitude of infection risks, but also to determine potential service needs and help 
to estimate the coverage of service provision. Together with its network of national partners (the Reitox network of 
National Focal Points) (176) and expert groups, the EMCDDA provides and implements a standardised 
methodology for estimating the size of problem drug user populations (including people who inject drugs) (4) 
which describes different methodological approaches to produce national and local estimates. 
Through a set of standardised monitoring tools (data tables and structured questionnaires), the EMCDDA also 
collects harmonised information about health and social responses to drug use and injecting drug use in the EU 
Member States, candidate countries, and Norway (112). Routinely collected data include information on drug 
prevention and harm reduction policies; on provision of health and social key interventions, including drug 
treatment (e.g. the number of clients receiving opioid substitution treatment); and on types, number and 
geographical distribution of needle and syringe programmes as well as the number of syringes provided. 
Surveillance of infections 
The epidemiological picture of infections among drug users may change rapidly, especially if prevention is weak. A 
good infectious disease surveillance system, built on the principle of ‘surveillance for action’, i.e. with an active link 
between prevention and surveillance structures, is a necessity if infection risks among people who inject drugs are 
to be controlled.  
ECDC coordinates case-based surveillance of all newly reported cases of blood-borne infections at the European 
level, including those infections that can be transmitted through the sharing of injection equipment. Case-based 
surveillance is useful for monitoring disease trends and may also be useful in the early detection of disease 
outbreaks, particularly if the national coverage of the system is good and reporting delays are minimal. The 
success of outbreak-response interventions are highly dependent on the ability to rapidly detect new outbreaks and 
having the means to respond appropriately. If national reporting is performed with some delay, this may be 
compensated by much faster local or regional reporting. EU-wide case definitions exist for HIV, hepatitis B, 
hepatitis C and hepatitis A infections, but the transmission category (i.e. risk factor) is systematically collected only 
for HIV infection (hepatitis B and C surveillance case definitions are currently under review and are anticipated to 
contain transmission category information). Many national systems, however, collect more detailed information, 
which is important for local prevention measure implementation. Disease notification rates may reflect disease 
incidence, but are usually an underestimation thereof. Additionally, only generic population denominator data can 
usually be applied to this type of surveillance. Changes in testing patterns and frequency can easily skew the 
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results. Case-based reporting also requires the maintenance of a basic level of infrastructure and processing time 
over substantial periods of time and requires significant support from healthcare providers to produce adequate 
risk factor information. 
The EMCDDA monitors the prevalence of infectious diseases in injecting drug users by developing data collection 
standards and guidance on bio-behavioural surveys and other data collection methods in injecting drug users (2). 
This work is done in close collaboration with ECDC, who coordinates general infectious diseases surveillance in 
Europe, and national and international partners (177-178). Data collection is focused around HIV and hepatitis B 
and C in injecting drug users. An early warning system and expert network are being maintained for infectious 
disease outbreaks in injecting drug users that can include other diseases, such as anthrax and botulism 
Other types of surveillance systems, such as various types of surveys and bio-behavioural studies, have their own 
distinct advantages in terms of providing strategically important information. Surveys can provide estimates of 
prevalence among the target population, which is usually not achievable through case-based surveillance. Bio-
behavioural surveys in injecting drug users, such as promoted by the EMCDDA and ECDC, can provide information 
on both drug use patterns and infectious diseases. However, these studies have to be repeated over time if trends 
are to be followed, which can be costly. An additional limitation is a lack of consensus on the best way to achieve 
representative sampling over time although this consensus is being built by the work of the two agencies.  
Countries should make decisions on the parameters of their own data collection systems for surveillance based on 
their own needs, but such a system should produce sufficient information to inform the development of a 
prevention strategy based on a health needs assessment of the local problem, while being efficient in terms of 
resources and costs.  
Monitoring and evaluation of programmes 
Monitoring systems should serve the needs of a country or a region for continuous process evaluation and 
adaptability to changes in user habits and profiles; such evaluation assists programme managers and policy makers 
in understanding which components of a prevention programme are successful and which require improvement. 
Monitoring can also indicate to programme planners and policy makers whether the mix of service delivery modes, 
the combination of services provided, and the coverage of interventions appears to be effective in reducing or 
preventing increases in the incidence of disease in the target group of people who inject drugs. If no monitoring is 
carried out, it will be impossible to measure programme impact or to attribute changes in behaviour or disease 
incidence to interventions. Both process and outcome indicators can be used and be useful, but it is worth to 
consider setting realistic goals for the latter category. Many hard outcome indicators such as prevalence of 
infections or changes in risk behaviour may take years or even decades to change significantly. 
Indicators 
This guidance does not cover the indicators for programme monitoring and evaluation in detail, as considerable 
work has already been conducted in this area (see (4,53,137)). It should be emphasised that all nationally 
monitored indicators should be used for national planning and evaluation purposes. Monitoring should be helpful, 
rather than a hindrance to achieving national or regional programme goals. Monitoring and evaluation data should 
feed into the process of continuous assessment and adaptation of service programmes in order to meet changing 
epidemiological and user characteristics. Obviously, not all national indicators are useful for international reporting, 
and not all international reporting indicators are necessarily useful for national monitoring. A frequent 
misunderstanding is to assume that all international indicators have to be rigorously followed, even if they are 
nationally irrelevant.  
Setting targets for intervention coverage 
At the population level, coverage is commonly defined as the proportion of the population in need of an 
intervention that actually received that intervention (179). In order to optimise prevention, it is crucial to know 
which proportion of the target population of people who inject drugs is reached by the specific preventive 
interventions. In the field of vaccines, the level of coverage determines the effects achieved by an intervention: at 
a certain level of coverage herd immunity effects introduce protection, even for unvaccinated populations. These 
findings are also supported by modelling studies. 
Common measures in the field of infectious disease prevention among people who inject drugs are the number of 
syringes distributed per injecting drug users per year, or the percentage of problem opioid users receiving opioid 
substitution treatment. The proportion of people who inject drugs receiving treatment for HIV, hepatitis B, and/or 
hepatitis C is another important indicator of the coverage of infection treatment services (180). Indicative targets 
for preventative services have been set, but it is indispensable to consider those in the context of the specific 
national (or local) situation, based on a well-performed needs assessment (53,179). There is growing evidence that 
higher levels of coverage of needle and syringe programmes and opioid substitution treatment are more effective 
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than lower levels of coverage per drug injector (71,181) and that large differences in coverage may exist between 
countries (180,182). According to data from the EMCDDA, the current EU average of syringes distributed in the 
year 2009 by specialist NSP facilities is 90 per drug injector. At national level, the highest reported number was 
over 300 syringes per injector (183). In addition, pharmacy sales constitute another major source of clean injecting 
equipment in most countries. In the same year, on average one in two problem opioid users received opioid 
substitution treatment, with the highest national percentage in Malta 68% (central estimate between 65% and 71% 
(128). Ideally, there should always be sufficient supplies of needles and syringes to keep services running. Unmet 
demand for needle and syringe exchange services or waiting times for drug treatment indicate an unmet demand 
for services and are a sign that service coverage needs to be increased.  
 
  
Scaling-up coverage of syringe programmes: experience from 
Estonia 
Estonia is one of the countries in the EU that has faced a heavy burden of injecting drug use, with a high rate 
of injecting drug use in the general population as well as a very high HIV prevalence among people who inject 
drugs. Injecting drug use is mostly concentrated in the capital city Tallinn and northeastern Estonia. It is 
estimated that Tallinn has about 10 000 injecting drug users who use mostly fentanyl analogues and 
amphetamines. Needle and syringe exchange services were initiated in Tallinn in 1997, and opioid substitution 
treatment with methadone followed in 2001, although the scale of services was limited. In 2005, HIV 
prevalence among people who inject drugs was 54% and a high proportion of new injectors (those injecting for 
<= 3 years) was reported (21%). It was decided at the national level that it was necessary to rapidly scale-up 
the coverage of prevention programmes in order to meet these increasing public health concerns, and this was 
planned into the National HIV/AIDS Prevention Strategy. Between 2003 and 2009, the number of fixed site and 
outreach service locations in Tallinn increased from 1 to 10, service visits increased 27-fold, the number of 
syringes distributed increased 43-fold (from 1.8 to 77 syringes/drug injector/year), and the number of positions 
for methadone treatment increased more than 4-fold. Approximately 80% of IDUs report ever being in contact 
with syringe exchange services, and for approximately 60% of users, syringe exchange services are the main 
source of clean needles and syringes. The percentage of people who inject drugs reporting sharing syringes 
during the last four weeks has decreased from 32% (2005) to 22% (2009). During that period, HIV incidence 
among new injectors decreased from 21% in 2005 to 9% in 2009, with the percentage of new injectors among 
all injecting users decreasing from 21% to 12%. It is likely that some of the decreased HIV incidence observed 
during the study period can be attributed to the scale-up of needle and syringe services, as access to drug 
treatment and antiretroviral treatment were provided at fairly low levels during that period. Continued provision 
of needles and syringes at even higher levels, combined with scale-up to high levels of drug and HIV treatment 
to those in need, is likely to further decrease HIV incidence in Estonia over time.  
Source: Uuskula et al., 2011 (206) 
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Annex A. Epidemiology of injecting drug use 
and major infections among people who 
inject drugs in the EU/EEA 
Injecting drug use 
People who inject drugs are one of the groups at highest risk of acquiring negative health consequences as a 
results of their drug use due to the risk of blood-borne infections like HIV and hepatitis B and C. They are also 
susceptible to drug overdose and infections such as tuberculosis, hepatitis A virus, bacterial skin infections, 
systemic infections, and sexually transmitted infections.  
In many European countries, injecting drug use is synonymous with opioid use, but there are some countries in 
which amphetamines are the predominant drug injected (5). The EMCDDA collects estimates of the prevalence of 
injecting drug use from European Member States and, in 2010, 12 countries provided recent estimates which 
suggested large differences in the prevalence of injecting drug use by country. The weighted average estimate of 
injecting drug users is 2.5 per 1000 adults aged 15 to 64 years for those countries providing estimates. If this 
average were extrapolated to the European population, it would correspond to an estimate of between 750 000 
and 1 million active injecting drug users in the EU/EEA. In addition to this, there is likely to be a significant 
population of former injecting drug users (5). While the injecting drug user population, as a whole, is aging in most 
of the western part of Europe, younger people who inject drugs have been highly prevalent in other parts of the 
EU.  
HIV 
HIV prevalence rates among people who inject drugs, as reported by EU countries range from less than 1% to 
more than 60% (based on specific studies or sentinel surveillance) (137). Of all newly diagnosed HIV cases 
reported in 28 countries in the EU/EEA Europe in 2009 (25 917 cases), 1 298 were identified as people with a 
current or past history of injecting drug use (a rate of 5.7 per 100 000 population). Despite the 2009 European 
average of 5% of reported HIV cases being due to injecting drug use, national figures varied widely, and the 
proportion of people who inject drugs among newly reported HIV cases ranged from 65% in Lithuania and 43% in 
Bulgaria to less than 1% in the Netherlands and Romania. Since 2004, the number of new HIV diagnoses reported 
among people who inject drugs has declined by 40% in the 26 EU/EEA countries with consistent HIV reporting 
systems (6). National trends have been similar, with most countries reporting declining numbers of cases of HIV 
among people who inject drugs during the last six years, except Bulgaria, Estonia, Latvia and Lithuania, with the 
three Baltic countries most affected by a rapid increase in rates of HIV diagnoses in 2001–02. Since then, these 
countries have reported declines, although a resurgence of HIV was reported in Latvia in 2007 and in Lithuania in 
2009. In west European countries the HIV epidemic among people who inject drugs is much older and peaked in 
the mid-1980s(6).  
Despite the decreasing trend of HIV cases among injecting drug users in the EU/EEA, there are still countries with 
populations of injecting drug users where significant HIV transmission is occurring (184). It is also likely that sexual 
transmission of HIV takes place between people who inject drugs and their sexual partners. Despite the relatively 
low absolute number of cases diagnosed among people who inject drugs, they are disproportionately affected by 
the HIV epidemic as compared to people who do not inject drugs.  
Hepatitis B and C 
Hepatitis B (HBV) and hepatitis C (HCV) viral infections are important public health issues for the European Union 
as both infections have substantial morbidity and mortality. Both infections may result in chronic disease which 
may lead to cirrhosis of the liver and possibly liver cancer and death. HBV and HCV can easily be transmitted 
through injecting drug use due to unsafe injection practices which include the sharing of needles and syringes and 
other injection materials.  
In Europe, injecting drug use is a major transmission route for HCV infections, and people who inject drugs 
account for the majority of newly reported cases of HCV infection. Estimates suggest that there are around one 
million current or former injecting drug users who may have chronic HCV infection in Europe (5). HCV infection 
rates are often very high amongst people who inject drugs, ranging from between 12% to 85% (54) and between 
50 and 90% of people who are infected with hepatitis C virus are unable to spontaneously eradicate the infection. 
The prevalence of HCV among people who inject drugs has been observed to be declining in nine countries in 
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Europe but increasing in three others, and data from four other countries shows no obvious trends (8). In six 
countries where risk factors are known, trends in notified cases of HCV have shown a drop in the proportion of 
people who inject drugs among notified cases, but an increase in three other countries (54). The data is difficult to 
interpret as data quality is often poor but there are indications that overall levels of HCV infection among people 
who inject drugs may be starting to decline. The risk of becoming infected with HCV is known to increase with 
injecting duration (10), but recent studies also indicate that many injectors contract the virus early in their injecting 
careers (54). The high levels of HCV infection among people who inject drugs is made worse by the fact that many 
of those who have contracted HCV through injecting drug use are unaware of their infection status. These factors 
indicate that early initiation of prevention measures is important.  
In addition to high levels of hepatitis C infection, people who inject drugs are often infected with other viruses, 
including hepatitis B or HIV. Having concurrent hepatitis infections greatly increases the risk of death due to 
sudden liver failure. Levels of hepatitis B antibodies are often very high among injectors but prevalence varies 
considerably between countries. This may be partly due to differences in vaccination levels among people who 
inject drugs (54). Recent data from nine European countries indicated that anti-HBc prevalence levels among 
people who inject drugs were over 40%. Among notified acute cases of hepatitis B with documented transmission 
routes, one in five cases has been infected by injecting drugs. Trend data indicate that the proportion of people 
who inject drugs among notified cases of HBV has declined in eight out of 17 countries between 2003 and 2008 
(54).  
Tuberculosis 
Injection drug use is associated with a multitude of environmental risk factors and risk behaviours. The 
combination of social risk factors such as poor living conditions, homelessness, incarceration, poverty, tobacco use 
and alcohol abuse, together with physiological effects of drug use, can place people who inject drugs at higher risk 
for developing TB, being infectious from TB, and at an increased risk of mortality (142,185). Further, HIV-induced 
immunosuppression is, as mentioned above, one of the most significant risk factors for the development of TB and 
a major reason for the high prevalence of TB among people who inject drugs. A recent systematic review of TB-
HIV co-infection in the EU/EEA found that the rate of HIV co-infection in TB patients ranged from 0 to 15%, and 
that injecting drug use was one of the risk factors for co-infection (186).  
The EU has some of the lowest TB notification rates in the world, but there is large heterogeneity between EU 
countries. In 2009, notification rates ranged between 2.8 and 108.2 cases per 100 000 population (187). The most 
vulnerable and excluded groups are the ones that carry the most significant burden of disease and which have the 
poorest access to services.  
There is no EU-wide collection of data recording of social risk factors for notified TB cases, therefore estimates on 
TB incidence in people who inject drugs rely on regional or, in some cases, country-specific studies. There is 
however ample evidence that drug use is associated with a higher prevalence of latent TB infection, and people 
who inject drugs are at increased risk of active TB disease. Depending on setting and country, about 10 to 60% of 
people who inject drugs test tuberculin skin test (TST) positive (142). Studies have shown that drug users, 
whether or not they inject drugs, face a similar risk of being TST positive (142). 
A large majority of M. tuberculosis-infected individuals never become ill, but bacteria persist in a subclinical status 
with minimal replication. Latent TB infection (LTBI) is therefore defined as the condition of an individual being 
infected, but without clinical manifestation of disease and from whom M. tuberculosis bacilli cannot be identified by 
culture. Active TB disease is diagnosed by evaluating the medical history, symptoms, radiography and 
microbiological or molecular identification of M. tuberculosis. The risk of progression to active TB disease is 
influenced by the individual’s immunologic status. People without HIV co-infection have a 5 to 10% lifetime risk of 
progressing to TB disease, while people with HIV have been reported to have a 5 to 10% annual risk of 
progressing to TB disease (185). 
Hepatitis A virus 
Hepatitis A is a viral illness with acute onset that is usually transmitted by fecal-oral contact, with outbreaks often 
traced to contaminated food and water supplies or to specific risk groups including men who have sex with men or 
people who inject drugs. Because it is not routinely monitored by risk group membership, the true burden of 
hepatitis A among people who inject drugs is unknown. There have, however, been reports of outbreaks of 
hepatitis A within the European Union concentrated in groups of people who inject drugs, such as in Latvia in 2008, 
where the population notification rate increased from 0.66 to 123 per 100 000 due to a community outbreak (13). 
Additional outbreaks have been linked to groups of people who inject drugs in the Czech Republic (12), Finland (15) 
and Norway (14). It is unclear whether these outbreaks were related to injection preparation practices or to other 
behaviours associated with poor hygiene.  
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Bacterial skin and systemic infections 
It is difficult to estimate the true extent of bacterial and systemic infections due to injecting drug use as most of 
these are not monitored at the European level. Based on a 2010 survey conducted in England, Wales and Northern 
Ireland, 40% of those currently injecting reported a sore, abscess or open wound, common symptoms of an 
injection site infection, during the previous year (17). These infections are typically the result of the use of non-
sterile injecting equipment or unclean drug preparation equipment. The most common pathogen that causes skin 
and soft tissue infections among people who inject drugs is Staphylococcus aureus, and a high proportion of this 
infection is methicillin-resistant Staphylococcus aureus (MRSA) (188). While most infections are minor, they can 
also become serious and systemic, resulting in osteomyelitis, bacteremia, septic deep-vein thrombosis, and 
endocarditis (189-190). Other bacterial skin, soft tissue and systemic infections are caused by group A streptococci 
(GAS), while still others are due to clostridial infections resulting in wound botulism or tetanus (191-192). 
Outbreaks of wound botulism (193), tetanus (18), and other clostridial infections (194) have been detected in 
people who inject drugs throughout Europe. While these systemic infections appear to be fairly rare, they can 
result in severe illness and death. Anthrax is one such acute disease caused by the bacteria Bacillus anthracis. It is 
rare in Europe, but in late 2009 and 2010, 42 cases were reported among injecting drug users in Scotland, 13 of 
which resulted in death. Further fatalities which were linked to the Scottish cases via the same anthrax strain were 
reported from England and Germany, and the source was thought to be a contaminated batch of heroin (54).  
Sexually transmitted infections 
The use of drugs, including injecting drugs, is associated with high-risk sexual practices and high prevalence of 
STIs, although the epidemiology of STIs among people who inject drugs is not well-documented in Europe. It is 
thought that people who inject drugs are at a higher risk of STIs because of the higher likelihood of exchanging 
sex for money or drugs or because of the impaired judgment in negotiating safer sex behaviour while under the 
influence of drugs (162). It has also been suggested that drug use may make it more difficult for some people who 
inject drugs to attend health services or STI screenings and that standard STI clinic services do not reach many 
people who inject drugs. Still, there is some evidence that sexual transmission of, for example, hepatitis B and HIV 
does occur between people who inject drugs and their sexual partners and, therefore, it is important to target this 
population for screening and prevention of sexually transmitted and other blood-borne viruses.  
Human T-lymphotropic virus type II (HTLV-II) 
HTLV-II is transmitted through shared injecting equipment, sexually, as well as through infected blood products. 
Since its discovery in 1982, human T-lymphotropic virus type II (HTLV-II) has held a controversial role as a 
pathogen, and literature on disease outcomes is limited. There is accumulating evidence of neurological disease 
and increased incidence of pneumonia, bronchitis and possible autoimmune disease among patients infected with 
HTLV-II (11). HTLV-II has been found among people who inject drugs in the United States and Europe, with an 
estimated prevalence of between 1.6 to 8% in Italy (195-196) and 0.4 to 11.5% in Spain (197). In these studies 
and others, HTLV-II co-infection with HIV is common. In northern Europe, HTLV-II is found at a comparatively 
lower frequency among people who inject drugs, but has been reported in Sweden (198) and France (199). One 
study in Ireland found a high seroprevalence (15%) of HTLV-II among people who inject drugs (200). 
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Annex B. Key interventions to prevent 
infections among people who inject drugs 
As described in the section on ‘Aims, objectives and methodology’, several factors were taken into account when 
generating the key intervention components indicated in this guidance. For each key intervention, evidence which 
was based on published peer-reviewed research was taken into account by carrying out a systematic review of 
reviews published since the year 2000 (‘review of reviews’ exercise) (201). Reviews are considered high-level 
evidence because they summarise and collate findings from the primary literature using systematic criteria to select 
the studies and assess their results. Reviewing reviews is an efficient method of bringing high-level evidence 
together, but has specific limitations (see technical reports on background evidence base). To compensate for 
those limitations, this guidance takes recently conducted primary research as well as expert opinions into 
consideration to complement the evidence statements based on the ‘review of reviews’. Outcomes of primary 
research were considered for interventions for which no systematic reviews were as yet available. The 
ECDC/EMCDDA Technical Advisory Group provided advice on all key intervention components.  
Additionally, we confirmed whether an intervention was considered best practice in the EU and thus featured in 
national and international guidance and policy documents. Finally, we also consulted studies of user and service 
provider preferences, in relation to how users/providers described their criteria for the most efficient delivery of 
prevention services. For each of the recommended key interventions, the considered judgement on how we 
weighed the evidence for the inclusion of the intervention in the guidance is provided.  
Table B1: Summary of the effectiveness of interventions to reduce injecting risk behaviour and the 
transmission of HIV and HCV, as a basis for the recommendation and considered judgement 
regarding seven key interventions  
Key intervention/ 
subcomponents 
Expert opinion/ 
implementation 
practices 
Evidence from review of 
published reviews 
(for symbols, see Table 
B2 below) 
Findings from primary studies 
Injection equipment 
 
Recommendation and considered judgement:  
Provision of, and legal access to, clean drug injection equipment, including sufficient supply of sterile 
needles and syringes, free of charge, as part of a combined multi-component prevention approach, 
implemented through harm-reduction, counselling and treatment programmes is recommended, 
based on consistent review-level evidence, primary studies and expert opinion.  
Needle and syringe provision Expert opinion in favour. Injecting risk behaviour: ++ 
HIV transmission: + 
HCV transmission: ? 
• Ecological studies of NSPs demonstrate 
stable or declining HCV transmission 
rates. 
• A recently published meta-analysis 
indicates that the combination of OST 
with NSP is effective in reducing HCV 
transmission. 
Other injecting paraphernalia  Expert opinion in favour. Injecting risk behaviour: + 
HIV transmission: ? 
HCV transmission: +/- 
In vitro studies demonstrate strong 
potential for transmission of HCV. 
Foil to stimulate route-
transmission 
Expert opinion in favour. Injecting risk behaviour: ? 
HIV transmission: ? 
HCV transmission: ? 
Lack of studies. 
Vaccination Recommendation and considered judgement:  
Vaccination of people who inject drugs with hepatitis B and A, tetanus and influenza vaccines, and – in 
particular for HIV-infected individuals – the pneumococcal vaccine. This is recommended based on 
expert opinion, implementation practice and primary studies. 
HBV, HAV, tetanus, influenza 
vaccines 
(pneumococcal vaccine for 
HIV-infected individuals) 
• Expert opinion in favour 
as a targeted service for 
people who inject drugs. 
• Vaccine efficacy is well-
established.  
• Widely implemented 
public health practice. 
(Not included in review) 
 
Strong evidence for individual and 
population-level reduction of HBV, HAV 
and tetanus following vaccination, even if 
only part of the full course is given. 
Drug dependence 
treatment 
Recommendation and considered judgment:  
Opioid substitution treatment (OST) and other forms of effective drug dependence treatment should 
be available and easily accessible, based on expert opinion and – in the case of OST – consistent 
evidence from multiple robust studies and reviews. While evidence of effectiveness of psychosocial 
treatments is lacking, it is recommended based on expert opinion.  
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Key intervention/ 
subcomponents 
Expert opinion/ 
implementation 
practices 
Evidence from review of 
published reviews 
(for symbols, see Table 
B2 below) 
Findings from primary studies 
Agonist (opioid) 
pharmacological treatment 
(OST) 
Expert opinion in favour. Injecting risk behaviour: ++ 
HIV transmission: ++ 
HCV transmission: + 
• Combination of OST with NSP further 
enhances effectiveness in preventing 
HCV transmission. 
• Increased adherence to ART and 
increased virological success of ART in 
HIV-positive persons on OST. 
• Use of OST in combination with 
psychosocial treatment is beneficial for 
compliance, completion of treatment 
and abstinence at follow-up. 
Antagonist pharmacological 
treatment 
• Option for those who do 
not commence agonist 
pharmacological 
treatment.  
• Further research needed. 
Injecting risk behaviour: +/- 
HIV transmission: +/- 
HCV transmission: +/- 
Potential benefits if combined with 
psychosocial treatment to reduce drug 
use. 
Psychosocial treatment Main option for stimulant 
users, in absence of 
pharmacological treatments; 
• enhances effectiveness of 
OST if combined 
• an option for opioid users 
not interested in 
pharmacological 
treatment 
Injecting risk behaviour: +/- 
HIV transmission: +/- 
HCV transmission: +/- 
• Potential benefits due to reductions in 
drug use 
• Contingency management may provide 
benefit for stimulant users 
• Combination with OST is beneficial for 
compliance, completion of treatment 
and abstinence at follow-up 
Testing Recommendation and considered judgement:  
Voluntary and confidential testing with informed consent for HIV, HCV (HBV for unvaccinated) and 
other infections including TB should be routinely offered and linked to referral to treatment. 
Infectious disease testing • Expert opinion in favour. 
• Included in national and 
international guidelines. 
• Widely implemented 
public health practice. 
• Necessary basis for any 
decisions on prevention 
and treatment. 
Injecting risk behaviour: +/- 
HIV transmission: ? 
HCV transmission: ? 
Studies and modelling suggest that 
efficient linkage to treatment access 
reduces forward transmission. 
Infectious disease 
treatment 
Recommendation and considered judgement:  
Based on evidence and expert opinion, antiviral treatment should be provided based on clinical 
indications to all those who are HIV, HBV or HCV infected. Anti-tuberculosis treatment should be 
provided for active TB cases. TB prophylactic therapy should be considered for latent TB cases. 
Treatment for other infectious diseases should be offered as clinically indicated. For all treatment, 
universal access is recommended, including access for active injectors9. 
 • Expert opinion in favour 
• Included in international 
and national guidelines, 
which increasingly state 
that active drug use 
should not be considered 
an exclusion criteria for 
receiving antiviral 
treatment.  
• Failure to treat could 
result in harm in the form 
of morbidity and 
potentially death.  
(Not included in review.) 
 
• Strong evidence for TB treatment of 
active and latent cases. 
• Modelling evidence suggests possible 
population-level prevention effects for 
HCV treatment 
• Evidence for HIV and HCV treatment 
success in cohorts of active drug users 
Health promotion 
(IEC and outreach) 
Recommendation and considered judgement:  
Health promotion focused on safer injecting behaviour; sexual health including condom use; and 
disease prevention, testing and treatment is recommended, based on evidence from reviews, primary 
studies and expert opinion. 
Information, education and 
counselling 
• Expert opinion in favour 
• Considered a fundamental 
companion component 
for the delivery of all of 
the other six interventions 
Injecting risk behaviour: + 
HIV transmission: +/- 
HCV transmission: ? 
• Multi-component package based on 
client populations’ specific needs 
• Supports prevention objectives 
 
                                                                    
 
9 Drug interactions and stable contact with a medical provider need to be considered.  
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Key intervention/ 
subcomponents 
Expert opinion/ 
implementation 
practices 
Evidence from review of 
published reviews 
(for symbols, see Table 
B2 below) 
Findings from primary studies 
Targeted delivery of 
services 
Recommendation and considered judgement:  
Services should be combined and organised and delivered according to user needs and local 
conditions; this includes the provision of services through outreach and fixed site settings, offering 
drug treatment, harm reduction, counselling and testing, and referrals to general primary health and 
specialist medical services.  
Fixed low-threshold sites 
offering NSP and other 
prevention services 
Expert opinion in favour, 
allows for client needs-
oriented service mix and 
gaining contact with users. 
The scientific literature was 
reviewed for NSP 
programmes 
 
Injecting risk behaviour: ++ 
HIV transmission: + 
HCV transmission: +/- 
• In individual studies, low prices, 
geographical proximity, encouraging 
staff attitudes and the option to receive 
additional services from a needle and 
syringe programme were facilitating 
factors for people who inject drugs to 
visit the service site.  
• Geographical distance, a fear of being 
caught by the police whilst attending an 
NSP, opening hours and a lack of 
privacy were found to act as barriers. 
Referrals to general primary 
healthcare services and to 
specialist medical, drug 
prevention, other harm 
reduction, counselling and 
treatment services 
Expert opinion in favour; 
included as a necessary and 
basic component of user 
care following accepted 
standards of health and 
social care delivery.  
 
The scientific literature was 
not formally reviewed in 
relation to the effect of 
referrals to services. 
The scientific literature was not formally 
reviewed in relation to the effect of 
referrals to services.  
Pharmacy syringe access Expert opinion in favour,  
broadens accessibility of 
sterile syringes. 
Injecting risk behaviour: + 
HIV transmission: +/- 
HCV transmission: ? 
Ecological and cross-sectional studies 
document decreased user syringe sharing 
following the introduction of syringe sales 
in pharmacies. 
Secondary distribution of 
syringes 
Expert opinion in favour,  
allows broadening the reach 
of syringe programmes. 
Injecting risk behaviour: +/- 
HIV transmission: +/- 
HCV transmission: ? 
Lack of studies. 
Outreach syringe provision Expert opinion in favour, 
allows to reach hard-to-
reach, marginalised 
populations.  
Injecting risk behaviour: ? 
HIV transmission: +/- 
HCV transmission: ? 
Lack of studies. 
Syringe vending machines Expert opinion in favour, 
allows syringe access 
independent of service 
opening hours. 
Injecting risk behaviour: +/- 
HIV transmission: +/- 
HCV transmission: ? 
Lack of studies. 
Multi mode injection 
equipment service delivery  
Expert opinion in favour,  
use of multiple distribution 
channels is recommended.  
The scientific literature was 
not formally reviewed in 
relation to the effect of multi 
mode service delivery. 
Evidence from primary studies that 
combination of channels of service 
delivery is more effective. 
Supervised injecting facilities Expert opinion in favour, 
allow ‘tailor-made’, 
individual safer use 
education. 
Injecting risk behaviour: + 
HIV transmission: ? 
HCV transmission: ? 
Lack of studies. Impact on overdose 
deaths in the community. 
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Table B2: Types of evidence statements and the level of evidence that was required to support each 
statement (modified from Ellis et al., 2003) 
Evidence statement Level of evidence 
 ‘++’ or ‘--' 
 
Sufficient review-level evidence to 
either support or discount the 
effectiveness of an intervention 
• Clear and consistent statement from one or more core reviews based on multiple robust 
studies, or 
• consistent evidence across multiple robust studies within one or more core reviews, in the 
absence of a clear and consistent statement in the review(s). 
 ‘+’ or ‘-’ 
 
Tentative review-level evidence to 
either support or discount the 
effectiveness of an intervention 
• A tentative statement from one or more core reviews based on consistent evidence from a 
small number of robust studies or multiple weaker studies, or 
• consistent evidence from a small number of robust studies or multiple weaker studies within 
one or more core reviews, in the absence of a clear and consistent statement in the 
review(s), or 
• conflicting evidence from one or more core reviews, with the stronger evidence weighted 
towards one side (either supporting or discounting effectiveness) and a plausible reason for 
the conflict, or  
• consistent evidence from multiple robust studies within one or more supplementary 
reviews, in the absence of a core review. 
 ‘+/-’ 
 
Insufficient review-level evidence to 
either support or discount the 
effectiveness of an intervention 
• A statement of insufficient evidence from a core review, or 
• insufficient evidence to either support or discount the effectiveness of an intervention (either 
because there is too little evidence or the evidence is too weak), in the absence of a clear 
and consistent statement of evidence from (a) core review(s), or 
• anything less than consistent evidence from multiple robust studies within one or more 
supplementary reviews. 
 ‘?’  
 
No reviews 
 No core or supplementary reviews of the topic identified, possibly due to a lack of primary 
studies. 
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Annex C. Additional guidance and technical 
guidelines  
Title  Organisation 
(year) 
Link 
Best practice portal: evidence 
base, standards and 
guidelines, and evaluated 
practice 
Key epidemiological indicators 
EMCDDA http://www.emcdda.europa.eu/best-practice 
http://www.emcdda.europa.eu/themes/key-indicators 
Use of interferon-gamma 
release assays in support of 
TB diagnosis 
ECDC (2011) http://ecdc.europa.eu/en/publications/Publications/1103_GUI_IGRA.pdf  
Guide to infection prevention 
in outpatient settings: 
minimum expectations for safe 
care 
CDC (2011) http://www.cdc.gov/HAI/pdfs/guidelines/Ambulatory-Care-04-2011.pdf  
EASL clinical practice 
guidelines: management of 
hepatitis C virus infection 
EASL (2011) http://www.easl.eu/assets/application/files/4a7bd873f9cccbf_file.pdf  
HIV testing: increasing uptake 
and effectiveness in the 
European Union  
ECDC (2010) http://ecdc.europa.eu/en/publications/Publications/101129_GUI_HIV_testing.pdf 
Guidelines for testing HIV, 
viral hepatitis and other 
infections in injecting drug 
users 
EMCDDA 
(2010) 
http://www.emcdda.europa.eu/publications/manuals/testing-guidelines 
Treatment of tuberculosis: 
guidelines, fourth edition.  
WHO (2010) http://whqlibdoc.who.int/publications/2010/9789241547833_eng.pdf  
Guidelines for services 
providing injecting equipment: 
best practice 
recommendations for 
commissioners and injecting 
equipment provision (IEP) 
services in Scotland  
Scottish 
Government 
(2010)  
http://www.scotland.gov.uk/Publications/2010/03/29165055/0 
Harm reduction at work: a 
guide for organizations 
employing people who use 
drugs 
Open Society 
Institute 
(2010) 
http://www.soros.org/initiatives/health/focus/ihrd/articles_publications/publications/h
armreduction-work-20110314/work-harmreduction-20110314.pdf 
Good practice guide: HIV and 
drug use – community 
responses to injecting drug 
use and HIV 
International 
HIV/AIDS 
Alliance (2010) 
http://www.aidsalliance.org/publicationsdetails.aspx?id=454 
Needle and syringe 
programmes: providing people 
who inject drugs with injecting 
equipment 
National 
Institute for 
Health and 
Clinical 
Excellence 
(NICE) (2009)  
http://www.nice.org.uk/nicemedia/live/12130/43301/43301.pdf 
International standards for 
tuberculosis care, second 
edition 
Tuberculosis 
Coalition for 
Technical 
Assistance 
(2009) 
http://www.tbcta.org/Uploaded_files/Zelf/ISTCReport2ndEdition1258118339.pdf  
Technical guide for countries 
to set targets for universal 
access to HIV prevention, 
treatment and care for 
injecting drug users 
WHO, UNODC, 
UNAIDS (2009) 
http://www.unaids.org/en/media/unaids/contentassets/dataimport/pub/manual/2010
/idu_target_setting_guide_en.pdf  
Guidance on testing and 
counselling for HIV in settings 
attended by people who inject 
drugs 
WHO, UNAIDS 
(2009) 
http://www.who.int/hiv/topics/idu/care/GuidanceTC_IDUsettings.pdf  
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Title  Organisation 
(year) 
Link 
Policy guidelines for 
collaborative TB and HIV 
services for injecting and other 
drug users 
WHO (2008) http://www.who.int/rpc/guidelines/9789241596930/en/index.html 
EASL clinical practice 
guidelines: management of 
chronic hepatitis B 
EASL (2009) http://www.easl.eu/assets/application/files/b73c0da3c52fa1d_file.pdf  
Safety, risks and outcomes 
from the use of injecting 
paraphernalia  
Scott (2008) http://www.scotland.gov.uk/Resource/Doc/127313/0057758.pdf 
 
Guide to starting and 
managing needle and syringe 
programmes 
WHO, UNAIDS, 
UNODC (2007) 
http://www.who.int/hiv/idu/Guide_to_Starting_and_Managing_NSP.pdf  
HIV/AIDS treatment and care: 
clinical protocols for the WHO 
European Region 
WHO (2007) http://www.euro.who.int/__data/assets/pdf_file/0004/78106/E90840.pdf  
Correlation – Guidelines on 
providing integrated outreach 
services  
Correlation 
Network 
(2007) 
http://www.correlation-
net.org/doccenter/pdf_document_centre/book_outreach_fin.pdf  
Ontario needle exchange 
programs: best practice 
recommendations 
Strike (2006) http://www.health.gov.on.ca/English/providers/pub/aids/reports/ontario_needle_exc
hange_programs_best_practices_report.pdf 
Policy and programming guide 
for HIV/AIDS prevention and 
care among injecting drug 
users  
WHO (2005) http://www.who.int/hiv/pub/prev_care/en/policyprogrammingguide.pdf 
Advocacy guide: HIV/ AIDS 
prevention among injecting 
drug users 
WHO, UNAIDS, 
UNODC (2004) 
http://www.who.int/hiv/pub/advocacy/en/advocacyguideen.pdf 
Evidence for action: 
effectiveness of community-
based outreach in preventing 
HIV/AIDS among people who 
inject drugs 
WHO (2004) http://www.who.int/hiv/pub/prev_care/evidenceforactionreprint2004.pdf 
Interim policy on collaborative 
TB/HIV activities. 1st ed.  
WHO (2004) http://whqlibdoc.who.int/hq/2004/WHO_HTM_TB_2004.330_eng.pdf  
BCG vaccine: WHO position 
paper 
WHO (2004) http://www.who.int/wer/2004/en/wer7904.pdf  
Background paper for the 
technical consultation on 
effective coverage of health 
systems 
WHO (2001) http://www.who.int/health-systems-
performance/technical_consultations/effcov_background.pdf  
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